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A SCREEN FOR PEPTIDES TARGETING CHEMORESISTANT METASTATIC 
TRIPLE-NEGATIVE BREAST CANCER 
Shraddha Subramanian, B.E 
Advisory Professor: Mikhail G. Kolonin, Ph.D. 
Cancer metastasis is the principal cause of most cancer-associated morbidities. While 
radiotherapy, hormone therapy, and novel therapeutic strategies, including immunotherapy, have 
shown promise in inhibiting tumor growth, chemotherapy remains the mainstay in the clinical 
management of metastatic progression. This is often the case in triple-negative breast cancer 
(TNBC), an aggressive breast cancer subtype where tumorigenesis is independent of HER-2, 
progesterone, or estrogen receptor expression. Despite improving TNBC prognosis, recent studies 
report that after chemotherapy administration, TNBC drug-tolerant tumor cell survival, relapse, 
and metastatic dissemination may be promoted. Overcoming drug resistance exhibited by 
metastatic tumor cells is a challenge owing to the lack of specific biomarkers and the absence of 
drugs available to selectively target them. The development of such therapeutics would be pivotal 
for cancer medicine, as they would enable targeted ablation of the mortality-responsible tumor 
cell population with minimal off-side effects.  
Our studies indicate that in TNBC mouse models, the chemotherapeutic agent cisplatin 
exacerbates spontaneous metastases to the lung. In this project, we have aimed to develop novel 
compounds that specifically target chemoresistant cancer metastases. It is based on the hypothesis 
that metastatic cancer cells express unique cell surface receptors that can be targeted. To test this 
hypothesis, we performed a combinatorial phage-displayed peptide library screen to isolate 
phage-displayed cyclic peptides that mimic the natural ligands of novel receptors expressed by 
chemoresistant metastatic TNBC tumor cells. These peptides were termed Breast Lung Metastasis 
Peptides (BLMPs), owing to their pulmonary metastases-specific tropism. Two lead BLMPs were 
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validated in murine cancer models in vivo and in vitro. We demonstrate that BLMP homing to 
pulmonary metastases was independent of chemotherapy administration. Our findings suggest 
that the BLMPs localized predominantly along the invasive edges of the pulmonary metastases. 
Immunofluorescence assays suggest that the two lead BLMPs are selective for tumor cells 
exhibiting a mesenchymal phenotype. BLAST sequence analysis of the two lead BLMP peptides 
reveals that they bear homology with biological ligands of receptors implicated in EMT activation 
and metastatic progression. To explore the therapeutic potential of these metastatic tumor cell-
specific peptides, the BLMPs were modified to generate hunter-killer peptides (HK-BLMPs) that 
induce apoptosis upon internalization into targeted cancer cells. We demonstrated that one of the 
HK-BLMP peptides selectively kills cancer cells and shows potential in decreasing metastatic 
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1. Breast Cancer  
1.1  Epidemiology  
The occurrence of breast cancer is heavily skewed by gender. Roughly 1 in 8 women 
have a lifetime risk of developing breast cancer, which is orders of magnitude higher than the 
corresponding risk in men - around 1 in 1000 (1). Nearly 25% of cancer diagnoses in women 
worldwide fall under the category of breast cancer (2), placing this disease second on the list of 
common causes of cancer death in women (3). Among women in the US, around 41,760 deaths 
were expected in 2019 from a projected 316,700 cases (4). Old age is the next major risk factor 
associated with breast cancer followed by factors like race, ethnicity, obesity, alcohol 
consumption, physical inactivity, early onset of menstruation, and late/no pregnancy. Advances 
in screening techniques, effective treatment, and early detection have contributed to a significant 
decrease in the death rate due to breast cancer (by about 40%) over the past 30 years (4).  Although 
these advancements merit praise, there has been no respite in the incidence of breast cancer, which 
continues to be on the rise. This necessitates a more comprehensive strategy to counter the disease 
while providing treatment that is both efficient and reliable. 
 
1.2  Breast Cancer Subtyping  
Building a systematic strategy for treating breast cancer requires an appropriate 
classification of its heterogeneity. Initial attempts used the presence or absence of estrogen 
receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 
(HER-2) to develop subtypes (5). Techniques like gene expression profiling are still gaining 
traction and require better standardization and cost-effectiveness before they can be used as a 
rubric for classification (6). From a clinical perspective, breast cancer continues to be subtyped 
on a molecular basis governed by the presence or absence of the receptors mentioned above. The 
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four resulting categories are Luminal A, Luminal B, HER-2, and TNBC. Their general relation 
with the three receptors is shown in Table 1.  
 
 ER PR Her-2 
Luminal A + + - 
Luminal B + + +/- 
Her-2 - - + 
TNBC - - - 
 
Table 1: Breast cancer subtyping: Classification based on hormone receptor expression 
 
1.2.1   Luminal A  
The presence of both estrogen and progesterone receptors, along with the absence of 
HER-2, characterizes the Luminal A subtype. This is the most commonly occurring subtype, and 
it exhibits a slow proliferation rate, which can be inferred through low Ki67 staining. Patients 
with Luminal A breast cancer generally receive the most favorable prognosis (7). Treatment for 
this subtype is typically contingent on the menopausal status of the patient and their estrogen 
source (8). The effectiveness of hormone therapy against Luminal A reduces the recurrence rate 
and increases the chance for survival (9, 10). Mutations in PIK3CA, MAP3K1, GATA3, and TP53 
genes are common in Luminal A.  
 
1.2.2   Luminal B  
This subtype's characteristics differ from Luminal A in one key feature - higher 
proliferation rates observable through greater Ki67 staining. Like Luminal A, they express 
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estrogen and progesterone receptors, but they may be HER-2 positive or negative. Diagnosis of 
this subtype often occurs at a young age, and the large tumor size associated with Luminal B 
typically results in poor prognosis. The survival rate for Luminal B patients is second only to 
Luminal A (10). The genes PIK3CA, GATA3, and TP53 are commonly mutated in Luminal B.  
 
1.2.3   HER-2  
As suggested by the name, this subtype has high expression levels of HER-2 and 
typically lacks both ER and PR expression. Patients with HER-2 breast cancer are diagnosed at 
an even younger age compared to the two Luminal subtypes. Targeted therapies against HER-2 
have gathered pace in recent years (10, 11).  These advances are improving the bleak prognosis 
that usually accompanies HER-2 breast cancer. The commonly mutated genes in this subtype are 
TP53, PIK3CA, and MUC16. These are accompanied by a higher expression of tyrosine kinases 
like fibroblast growth factor receptor (FGFR) and epidermal growth factor receptor (EGFR).  
 
1.2.4   TNBC  
TNBCs represent a subtype of breast cancers that lack the expression of ER, PR, or 
HER-2 genes. It is commonly observed in young patients and accounts for over 15% of newly 
diagnosed breast cancer cases (12). At the time of diagnosis, most TNBCs are found to have 
progressed to an advanced stage due to the higher grade, larger size, and lymph node involvement 
presented by TNBC tumors (13). An additional level of complexity observed to accompany 
TNBCs is intra-tumoral and inter-patient heterogeneity (14). Although all TNBC tumors present 
a similar gene expression profile, their mutation burden is often non-uniform. No two TNBC 
tumors have the same mutations, which accounts for the high inter-patient heterogeneity 
encountered clinically. Moreover, the genetic composition of TNBC tumors and thus, their 
prognosis varies from patient to patient. TNBCs harbor mutations in vital tumor suppressors such 
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as p53 and BRCA (15). Several critical signaling pathways, including the phosphatidylinositol 3-
kinase and protein kinase B (PI3K-AKT) pathway, mitogen-activated protein kinase (MAPK), 
nuclear factor kappa light chain enhancer of activated B cells (NF- B) pathway, and wingless and 
int-1 (Wnt) pathway, are often dysregulated in this cancer subtype (16). To gain more insight into 
the intra-tumoral diversity exhibited by TNBCs, a classification based on gene expression profiles 
was performed in 386 TNBC tumors (13). This clustering revealed six new TNBC subtypes 
namely basal, mesenchymal, mesenchymal stem-like (MSL), immunomodulatory (IM), luminal 
androgen receptor (LAR), basal-like 1 (BL1), and basal-like 2 (BL2), each characterized by a 
unique gene and pathway signature (13). For instance, the LAR subtype showed enrichment in 
metabolic pathways and androgen receptor signaling, while the BL1 subtype exhibited enrichment 
in DNA replication and cell cycle pathways (13). Another seminal study that analyzed the RNA 
and DNA profiles of 198 TNBC tumors classified them into four distinct molecular subtypes: a) 
Luminal androgen receptor (LAR) subtype with up-regulated cell surface mucin expression, b) 
Mesenchymal (MES) subtype overexpressing platelet-derived growth factor receptor (PDGFR) 
and c-kit growth factor receptors, c) Basal-like immune-suppressed (BLIS) subtype expressing 
the immune-suppressing molecule V-set domain-containing T-cell activation inhibitor (V-
VTCN1) and lastly, d) Basal-like immune activated (BLIS) subtype which expresses signal 
transducer and activator of transcription-3 (STAT-3) molecules and cytokines (17).  
 
2. Metastatic Breast Cancer  
Metastasis is a convoluted biological phenomenon. It involves cancer cell dissociation 
from the primary tumor, invasion of surrounding connective tissue, intravasation into host 
vasculature, and entry into circulation. Upon survival in circulation, the tumor cells disseminate 
to secondary sites harboring a permissible tumor microenvironment (TME). Here, they 
extravasate and form micro-metastases, establish a favorable metastatic niche, and eventually 
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proliferate into macro-metastases (18). The ability to complete each stage of the metastatic 
cascade dictates the metastatic potential of the tumor cells. 
Although localized primary tumors are the source of malignancy burden, it is the 
metastases that attribute to over 90% of all cancer-associated morbidity and mortality (19). Owing 
to the genetic instability of metastatic tumors, their treatment is a daunting challenge. In addition 
to a unique immunophenotypic profile, TNBCs possess several aggressive clinicopathological 
features such as young age of onset and large tumor size (20). These factors promote the 
development of distant metastases in several organs, including the lung, brain, and liver. 
A large cohort study of over 1600 women with invasive breast cancer reported that the 
TNBC patient subgroup reflected tumors that were more aggressive and grew rapidly (21). These 
observations were further corroborated by Liedtke and colleagues, who revealed that TNBC 
patients had higher recurrence rates when compared to their hormone-sensitive counterparts (22).  
Further, these tumors often resemble basal-like breast cancers, which are identified as 
poor prognosis subgroups with respect to relapse-free survival and overall survival (OS) (23). The 
gene expression profile of most basal-like tumors consists of a myriad of candidate genes that 
might contribute to their aggressive phenotype. Since TNBCs and basal-like cancers are believed 
to reflect a higher level of genetic instability, it might explain their propensity towards metastatic 
progression. Thus, to improve metastatic TNBC (mTNBC) patient outcomes, it is crucial to gain 
insight into the cellular and molecular mechanisms that govern metastatic dissemination (24).  
 
3. Epithelial to Mesenchymal Transition and Breast Cancer Metastasis 
Epithelial to mesenchymal transition (EMT) is a latent developmental program 
implicated in wound healing and tissue regeneration (25). EMT is accompanied by a loss of 
apicobasal cell polarity, disruption of adherens junctions, and cytoskeletal reorganization by 
which cells acquire a mesenchymal and migratory phenotype (26). In cancer, a hijacked EMT 
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program endows metastasis favoring characteristics upon the cancer cells (27). An 
armamentarium of cell surface markers, cytoskeletal organization proteins, transcription factors, 
microRNAs, ligands, and growth factors work in unison to choreograph this intricate process (28). 
The reverse process, termed mesenchymal to epithelial transition (MET), is also highly regulated 
during development (28, 29). Distant metastases resemble the molecular subtype of their primary 
tumor, and several studies have proved that the disseminated cancer cells are often epithelial (30, 
31). The term plasticit  describes the abilit  of cells to transition seamlessl  between the 
epithelial and mesenchymal phenotypes. While the migratory and invasive features of cancer cells 
initiate the metastatic cascade, its completion is contingent upon the plasticity between 
EMT/MET (32).  
EMT is primarily induced through alterations in gene expression, that enables cells to 
acquire mesenchymal properties. During EMT, cells demonstrate epithelial cadherin (E-cadherin) 
repression and neural cadherin (N-cadherin) up-regulation simultaneously (33). The cadherin 
switch, a prominent EMT hallmark, is observed regardless of cell type or EMT-inducing factor 
(34). The Snail family of transcription factors induces the mesenchymal phenotype through the 
epigenetic inhibition of E-cadherin. Snail is also responsible for turning on the expression of 
mesenchymal markers such as N-cadherin, collagen, fibronectin, matrix metalloproteases 
(MMPs), Twist, and zinc finger e-box binding homeobox-1 (ZEB-1) (34). EMT can also be 
triggered by hypoxia and other extracellular stimuli, including tumor necrosis factor-alpha (TNF-
), transforming growth factor-beta (TGF- ), EGF, FGF, and PDGF, to name a few. Signal 
transduction pathways, including Wnt, Notch, NF- B, MAPK, and PI3K pathways, are also 
reported to coordinate the EMT program (35). The transcriptional factors and the hallmarks of 
EMT are often associated with a malignant phenotype in breast cancer patients. The high 
expression of Slug and Twist was demonstrated to closely correlate with poor prognosis in breast 
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cancer patients (36, 37). Further, Jeong and colleagues underscored that EMT was related to a 
high histological grade and the triple-negative phenotype (38).  
 
4. Treatment Modalities of Triple-Negative Breast Cancer 
Patients with TNBC fail to respond to hormone-based therapy due to the absence of 
ER, PR, and HER-2 target receptor expression.  Thus, surgery and chemotherapy, individually or 
in combination, continue to remain viable treatment modalities in clinical TNBC management. 
However, recent studies have reported the discovery of novel receptors that could serve as targets 
for the development of new anti-cancer therapeutics. 
 
4.1  Surgery  
Breast-conserving surgery (BCS) and mastectomy are primary candidates in TNBC 
treatment. TNBC status, traditional clinicopathological variables, and patient preference 
determine whether mastectomy or lumpectomy is the optimal treatment choice. A 2016 
population-based study published in Lancet Oncology reported a higher survival in patients 
subjected to BCS and radiotherapy as opposed to patients that underwent mastectomy (39). 
Another study concluded that post BCS, the local recurrence rate was lower in TNBCs than other 
breast cancer subtypes (40).  
 
4.2  Chemotherapy  
Cytotoxic chemotherapy remains the mainstay of TNBC treatment despite the 
development of novel targeted therapies. Factors such as tumor size, lymph node status, grade, 
and overall performance status are used to design individualized chemotherapy regimens for 
TNBC patients (41). Several studies have underscored the benefit of using chemotherapeutic 
drugs in the neoadjuvant, adjuvant, and metastatic treatment of TNBC. The administration of 
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neoadjuvant chemotherapy has consistently shown higher response rates (RR), thus promoting 
improved long-term outcomes in TNBC. Additionally, a higher pathologic complete response 
(pCR) related to neoadjuvant chemotherapy is observed in TNBCs when compared to luminal 
non-TNBC subtypes (42). Although TNBCs are initially susceptible to chemotherapy, early 
complete response (CR) often fails to correlate with OS. On the other hand, TNBC specific 
adjuvant regimens that appear to be efficacious remain incompletely defined for both early 
advanced stages of the disease. Currently, the chemotherapeutic strategies employed in the 
management of TNBC are a) platinum compounds and taxanes targeting DNA repair complexes 
and p53, b) anthracycline-based regimens targeting cell proliferation, and c) third-generation 
chemotherapeutics using either dose-dense or metronomic polychemotherapy. 
 
4.2.1   Platinum Salts 
Due to the improvements in managing the non-specific toxicity of platinum agents, a 
renewed interest in using DNA cross-linking agents (cisplatin and carboplatin) in TNBC treatment 
has emerged. Further, the histological similarities between breast cancer type 1 susceptibility 
(BRCA1)-mutated breast cancers and TNBCs, render platinum agents, a desirable therapeutic 
strategy. The cytotoxicity of platinum agents is primarily exerted through the formation of mono 
adducts, thus distorting the DNA double helix, to generate single and double-strand DNA breaks 
(43). Preoperative TNBC therapy with platinum agents has yielded promising results. For 
instance, a phase II study evaluating single-agent cisplatin in women with stage II or III TNBC 
reported a pCR rate of 22%, with 36% of the patients demonstrating a Miller-Payne score of 4 or 
5 which included both complete and near-complete responses (44). The success of platinum 
agents in preoperative settings further bolstered the rationale behind their use in advanced TNBCs. 
In the TBCRC009 trial, mTNBC patients received either cisplatin or carboplatin for three weeks. 
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A median progression-free survival (PFS) of 89 days was observed, with 33% of patients 
reporting a PFS less than six weeks, while another 33% had a PFS longer than six months (45). 
 
4.2.2.  Taxanes 
Taxanes are a class of diterpenes that function through the disruption of microtubule 
function (46). While taxanes remain an essential treatment modality in TNBCs, it does not 
demonstrate any specific benefit over non-TNBCs (42). In an MD Anderson Cancer Center 
(MDACC) study evaluating 1,118 patients treated with neoadjuvant anthracycline and taxane 
combination therapy, the pCR rates were observed to be significantly higher in TNBC patients, 
but both PFS and 3-year OS were substantially worse (22). The benefit of using taxanes in 
adjuvant TNBC therapy has gained traction only recently. In the CALGB 9344/INT1048 trial,  
randomized patients with node-positive operable breast cancer received three doxorubicin doses 
followed by four paclitaxel cycles every three weeks. The addition of paclitaxel was associated 
with significant improvements in the HER-2 negative, TNBC patient cohort (47). Abraxane, a 
novel nanoparticle albumin-bound (nab) formulation of paclitaxel, demonstrated a significantly 
improved PFS in mTNBC patients both alone and in combination with other chemotherapy (48). 
However, the NSABP B28 trial comparing cyclophosphamide and doxorubicin with or without 
paclitaxel found no significant difference in the relative risk of disease recurrence or OS based on 
hormone receptor status (49). In the metastatic setting, several trials reported no specific benefit 
of using taxanes in TNBC treatment. The CALGB9342 trial, which evaluated three different 
paclitaxel doses for metastatic hormone receptor-positive tumors and mTNBCs, reported no 





4.2.3   Anthracyclines and Cyclophosphamides 
Anthracyclines act through multiple mechanisms, including DNA intercalation, 
topoisomerase-II mediated toxicity, reactive oxygen species (ROS) generation, and DNA adduct 
formation, making them one of the most efficacious anti-cancer treatments ever developed (51). 
On the other hand, cyclophosphamide promotes the formation of phosphoramide mustards, that 
irreversibly crosslink with DNA to facilitate tumor cell apoptosis. In the study by Dees and 
colleagues, the pathological and clinical RRs for neoadjuvant anthracycline and 
cyclophosphamide (AC) combination chemotherapy were reported to be significantly higher in 
TNBC patients than in other subtypes (52). Another study by Rouzier and collaborators reported 
a pCR rate as high as 45%, following preoperative paclitaxel treatment combined with 
fluorouracil, doxorubicin, and cyclophosphamide (53). The WSG 01 trial corroborated the benefit 
of using adjuvant anthracycline therapy in young patients with TNBC. Most of the patients 
showed a 5-year event-free survival rate (54). The anthracyclines doxorubicin, epirubicin, and 
etoposide are commonly used in the treatment of mTNBC (55). 
 
4.2.4   Anti-Metabolites 
Anti-metabolites hinder cancer cell proliferation through the incorporation of 
chemically altered nucleotides or the depletion of deoxynucleotides required for DNA replication. 
In the clinical trial conducted by Kroman and collaborators, the addition of gemcitabine to 
paclitaxel promoted an increase in RR (40.8% vs. 22.1%) and more prolonged survival (median 
survival 18.5 vs. 15.8 months) in patients with advanced mTNBC (56). Further subgroup analysis 
of two large randomized adjuvant capecitabine trials indicated that the addition of capecitabine to 




4.3  Novel Potential Therapies  
As mentioned previously, TNBC patients demonstrate a relatively poorer disease 
prognosis than other breast cancer subtypes. Extensive molecular and genetic profiling studies 
have identified several different targetable mutations. In addition to the mutations in PIK3CA and 
p53, other potential targets such as PTEN, INPP4B, KRAS, BRAF, EGFR, FGFR, IGFR1, KIT, 
and MET have been explored (59). The recent characteri ation of TNBC s diverse subt pes and 
molecular drivers has provided extensive insight into its heterogeneity. Further, it has led to the 
evolution of in vitro and in vivo models that accurately recapitulate TNBC tumorigenesis, thus 
providing the pre-clinical platforms required to develop novel therapeutic strategies.  
 
4.3.1   Poly ADP-Ribose Polymerase Inhibitors 
Some TNBCs resembling basal-like breast carcinomas frequently harbor defects in 
DNA double-strand break repair due to BRCA-1 dysfunction. Such BRCA1-deficient tumors 
exhibit high sensitivity to poly ADP-ribose polymerase (PARP) inhibition. PARP enzymes play 
a pivotal role in the processing and repair of DNA breaks (60). In vitro, pre-clinical studies have 
revealed that breast cancer cells lacking BRCA1/2 function exhibit a higher sensitivity to PARP 
inhibitors (61). Olaparib and Iniparib are the PARP inhibitors showing the most potential. A 
clinical trial using DNA-damaging agents and PARP inhibitors (olaparib) in conjunction has 
shown promising results in BRCA1/2-deficient TNBC patients with advanced disease progression 
(62, 63). Further, a randomized phase II study revealed that the clinical benefit rate, overall RR, 
and PFS in mTNBC patients was significantly higher when Iniparib was added to carboplatin and 
gemcitabine (64). A similar improvement in mTNBC patients was observed when Iniparib was 




4.3.2   PI3K-AKT-mTOR Pathway Inhibitors 
Owing to its multi-faceted role in promoting protein translation, tumor angiogenesis, 
cancer cell proliferation, and migration, the mammalian target of rapamycin (mTOR) is a lucrative 
anti-cancer therapeutic target (66). Currently, rapamycin and its analogs everolimus, 
temsirolimus, and deforolimus are undergoing clinical evaluation in TNBC treatment (67). The 
mesenchymal TNBC subtype, enriched in EMT and stem-cell like features, has demonstrated 
some benefit from mTOR inhibition. Further, the MDA-MB-435 TNBC cell line harboring 
phosphatase and tensin homolog (PTEN) deficiency has shown increased sensitivity to mTOR 
inhibition (68), thus prompting the use of mTOR inhibitors in TNBC patients with PTEN loss 
(13). Several reports have attributed cisplatin resistance to mTOR activation, a phenomenon 
reversed by everolimus administration. Beuvink and colleagues revealed that the addition of 
everolimus to cisplatin increased the loss of viability by 5- fold in vitro (69). Additionally, clinical 
trials are also exploring the potential of targeting the AKT pathway in TNBC patients. For 
instance, a phase II study reported a longer PFS and OS in 140 mTNBC patients upon the addition 
of the AKT inhibitor capivasertib to paclitaxel (70). 
 
4.3.3   Immune Checkpoint Inhibitors 
The inception of immune checkpoint inhibitors (ICI) targeting programmed death-1 
(PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T lymphocyte antigen-4 (CTLA-4) 
has drastically altered the treatment landscape for cancers like TNBC with a high mutational 
burden (71). Several studies have suggested that the TNBC subtype is an attractive candidate for 
cancer immunotherapy due to the presence of PD-1 positive TILs (tumor-infiltrating 
lymphocytes) and higher rates of PD-L1 expression by the tumor and the immune cells (72, 73). 
Pembrolizumab, a PD-1 inhibitor, was recently evaluated in a phase II, single-arm study in 
patients with advanced TNBC (74). Results from the phase I trial evaluating the PD-L1 inhibitor 
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atezolizumab in TNBC revealed an OR of 10% in a cohort of 112 patients, and a notable 11 
responders were alive at two years (74). As monotherapy for advanced TNBCs, ICIs have resulted 
in RRs ranging between 5% to 19%, with higher RRs based on PD-L1 status (75-77). However, 
median PFS was observed to be only about 1.4 to 2.1 months. To date, atezolizumab is the only 
FDA approved ICI used as first-line therapy in patients with advanced TNBC (78). 
 
4.3.4   EGFR Inhibitors 
Overexpression of EGFR is a common phenomenon observed in TNBC. This tyrosine 
kinase receptor plays a crucial role in regulating PI3K AKT mTOR pathway and 
ras/raf/mitogen-activated protein kinase/ERK kinase (RAS-MEK) pathway mediated tumor cell 
proliferation, survival, and differentiation (79). Anti-cancer monoclonal antibodies (mAbs) 
targeting dysregulated EGFR activity act through the following mechanisms: a)  tumor cell death 
through inhibition of receptor dimerization, inhibition of cell survival signaling and ligand-
receptor blockade (80, 81), b) activating antigen-specific T cell immunity (82), c) complement-
mediated cytotoxicity (83). Cetuximab is a chimeric IgG1 mAb that binds and blocks ligand-
induced EGFR in tumor cells (84). In pre-clinical studies, cetuximab effectively inhibited TNBC 
tumor growth alone and in combination with chemotherapy (85). Further, in phase 2 trials, TNBC 
patients receiving cetuximab combined with cisplatin had a significantly longer median PFS than 
patients treated with cisplatin alone (86). When Lapatinib (an EGFR tyrosine kinase domain 
inhibitor) was combined with rapamycin, they produced a gradual dose-dependent growth 
inhibition in MDA-MB-231 and MDA-MB-468 TNBC cell lines in vitro (87). 
 
4.3.5   Angiogenesis Inhibitors 
Tumor-specific vascular endothelial growth factor (VEGF) expression is observed to 
be significantly higher in TNBCs when compared to non-TNBC presentations. The anti-VEGF 
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agent, Bevacizumab (Avastin®), has received controversial attention despite showing potential in 
several clinical trials. However, multiple Phase III trials are investigating the efficacy of 
bevacizumab in the mTNBC setting (88). In the E2100 trial, the addition of bevacizumab to 
paclitaxel, doubled the median PFS (5.3 versus 10.6 months), while reducing the risk of 
progression by 51% in first-line mTNBC patients (89). The AVADO trial demonstrated a 47% 
reduction in mTNBC disease progression when bevacizumab was added to docetaxel (90). In the 
neoadjuvant setting, the GeparQuinto trial studying the effect of combining bevacizumab with 
anthracycline taxane chemotherapy, demonstrated a statistically significant improvement in pCR 
rates (N = 663; 39.3% versus 27.9%, P = 0.003) for patients receiving bevacizumab compared 
with chemotherapy (91).  
 
5. Mechanisms of Triple-Negative Breast Cancer Chemoresistance 
Despite numerous advances in cancer therapeutics, chemotherapy remains the mainstay 
in systemic TNBC treatment. Neither anti-HER-2 agents nor hormonal therapies are efficacious 
owing to the absence of their targets in the TNBC setting (92). Cytotoxic chemotherapy induces 
cancer cell death primarily through apoptosis. As depicted in Figure 1, although chemotherapy 
administration initially promotes tumor regression, chemoresistance is eventual as tumor cells 
evade drug exposure by turning to alternative cellular fates, thus promoting metastatic recurrence 





Figure 1: Chemoresistance promotes metastatic recurrence. Primary tumor cells that survive 
chemotherapy administration acquire an invasive phenotype and undergo metastatic 
dissemination to distant organs.  
 
5.1  ATP-Binding Cassette Transporters 
Transporter-mediated drug efflux is one of the most extensively validated mechanisms 
of chemoresistance (93). ATP-binding cassette (ABC) transporters utilize ATP binding to 
translocate various substrates, including anti-cancer drugs across the cell membrane. The three 
ABC transporters most frequently upregulated in TNBCs are a) multidrug-resistant protein-1 
(MRP-1), which confers resistance against vinca alkaloids, high-dose methotrexate, and 
anthracyclines. b) P-glycoprotein (MDR-1), which effluxes a broad spectrum of taxanes such as 
paclitaxel out of cancer cells, and c) breast cancer resistance protein (ABCG-2), which pumps out 
drugs such as doxorubicin (94).  
 
5.2  Mutations in DNA Replication and Mismatch Repair Enzymes 
DNA damage is the primary mechanism of action of most conventional 
chemotherapeutics. Several studies have suggested chemoresistance to be a result of aberrant 
DNA damage repair due to altered DNA mismatch repair enzyme function. For instance, 
chemoresistance against anthracyclines and epipodophyllotoxins was attributed to mutations in 
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the critical DNA replication and repair enzyme topoisomerase II (95, 96). The study by Fedier 
and colleagues further confirmed that the resistance to topoisomerase II inhibitors was due to 
inhibited expression of DNA-mismatch repair proteins (97).  
 
5.3  Tumor Dormancy  
Following chemotherapy administration, chemoresistant tumor cells sometimes exist 
in a dormant state for several years before resuming proliferation. These dormant cancer cells 
adapt by entering quiescence and undergo alterations in their signaling pathways, protein 
expression, and modulation to survive chemotherapy-induced cytotoxic stress. Post-treatment, 
these cells re-initiate tumor growth, which promotes disease recurrence after an initial response.  
Tumor dormancy may be established through chemotherapy-induced cellular senescence (CIS), 
which results in permanent cell cycle arrest without cell death. Although this stress response 
reduces tumor growth, cancer cells often exit CIS and regain proliferative capacity. The effect of 
chemotherapy on the senescence-linked signaling via p53, p16lnk4a, p21Waf1/Cip1, and 
p27Kip1, resulting in tumor dormancy, continues to be a hotly debated topic. 
 
5.4  Epithelial to Mesenchymal Transition 
Several recent studies suggest the involvement of EMT in antagonizing 
chemosensitivity in several cancers, including TNBC. As discussed previously, EMT entails the 
dynamic transition promoting the acquisition of invasiveness, resistance to apoptotic stimuli, 
motility, and a mesenchymal phenotype by epithelial cancer cells (98). Aberrant expression of the 
Snail family of transcription factors not only initiates EMT but also confers resistance to apoptosis 
induced by genotoxic stress in MDA-MB-468 and MDA-MB-231 TNBC cell lines in vitro (99). 
Compelling evidence also demonstrated that the EMT inducer Twist up-regulated ABC 
transporter expression, which leads to multidrug resistance in human breast cancer cell lines (100, 
 18 
101). Twist is implicated in the activation of the -catenin signaling pathway and AKT pathways, 
known to reinforce the loss of chemosensitivity (102).  
 
5.5  Cancer Stem Cells 
Growing evidence indicates that cancer recurrence is caused by multipotent self-
renewing cancer-initiating cells, commonly referred to as cancer stem cells (CSCs). The CSC 
paradigm has emerged based on the notion that some, but not all, cancer cells have the potential 
to recapitulate the phenotypic diversity of the original tumor upon transplantation.  The biological 
features of CSCs largely overlap with those of drug-resistant cancer cells. Recent studies suggest 
that upon exposure to conventional chemotherapy, TNBC biopsies demonstrate an increase in 
RNA transcripts of genes associated with the CSC phenotype. For instance, treatment with 
taxanes like paclitaxel significantly increased TGF-  signaling and other CSC properties in 
several TNBC cell lines and mouse xenografts (103). The TGF-  c tokine famil  and its receptors 
are often overexpressed in CSCs. Through TGF-  induced EMT, CSCs promote TNBC relapse 
(104). Another study reported elevated expression and transcriptional activity of hypoxia-
inducible factors (HIFs) post gemcitabine administration in TNBC cell lines. This eventually 
promoted CSC enrichment through upregulated IL-6 and IL-8 signaling (105).  
 
5.6  Hypoxia 
A prominent feature of the tumor milieu is hypoxia, where an inadequate supply of 
oxygen occurs due to tumor cells outgrowing their vasculature (106). Clinically, TNBC tumors 
are found to be more hypoxic than their non-TNBC counterparts (41). By varying the oxygen 
levels within the TME, hypoxia propagates a chemoresistance phenotype that is accompanied by 
tumor aggressiveness and metastatic dissemination. Hypoxia promotes the development of an 
acidic TME, thus compromising chemotherapy drug uptake (107). Further, hypoxia protects 
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tumor cells against immune surveillance by acting as a barrier to immune effector cells (108). 
Additionally, hypoxia stimulates cellular adaptations including; a) upregulated ABC transporter 
expression, b) decreased proliferation, c) autophagy induction, d) upregulation of pro-angiogenic 
factors, e) enhanced genetic instability and subsequent clonal selection of aggressive phenotypes 
and f) E-cadherin repression which furthers cancer progression (109). 
 
5.7  Cell-Signaling Pathways 
5.7.1   NF- B Pathway  
A crucial regulator of carcinogenesis, the NF- B signaling pathwa , inhibits apoptosis, 
controls the inflammatory response, and angiogenesis. Hyperactivation of the NF- B pathwa  is 
often implicated in TNBC progression and poor prognosis. In 2018, Huang and colleagues 
demonstrated that doxorubicin administration stimulated the overexpression of pleiotrophin 
(PTN) and its cognate receptor protein tyrosine phosphatase zeta (PTPRZ1) in several TNBC cell 
lines. The upregulated PTN/ PTPRZ1 signaling axis subsequently promoted chemoresistance 
evolution through the activation of the NF- B signaling pathwa  in vitro (110). Alternatively, that 
NF- B signaling can also be up-regulated by hypoxia (111).  
 
5.7.2   PTEN and PI3K-AKT-mTOR Pathway  
PI3K-AKT-mTOR (PAM) pathway is a critical mechanism governing cancer cell 
survival, growth, proliferation, and motility. Frequent up-regulation of the PAM pathway 
accounts for the adverse prognosis, aggressive nature, and poor outcome observed in most TNBCs 
(112). Further, the skewed expression of the PAM pathway components is also associated with 
TNBC chemoresistance (113). Additionall , the PAM pathwa s AKT induces HIF-1, which 
plays a notable role in chemoresistance onset (114).  
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5.7.3  JAK/STAT pathway  
Aberrant JAK/STAT signaling plays a pivotal role in mediating the metastatic cascade 
(115). Genetic profiling of chemotherapy-refractory TNBCs revealed a pro-inflammatory gene 
signature due to JAK/STAT pathway extracellular ligand (Interleukin (IL)-6/IL-8) overexpression 
(116). STAT-3, which is a downstream component of the JAK/STAT signaling axis, is frequently 
overexpressed in TNBC. STAT-3 interacts with NF- B to promote chemoresistance in TNBC 
(117). Moreover, through the up-regulation of both HIF-1 and ABC transporter expression, 
STAT-3 also induces hypoxia-mediated chemoresistance in TNBC (118).  
 
5.7.4   TGF-  Pa h a   
While the TGF-  signaling pathwa  is s non mous with EMT, proliferation, 
angiogenesis, and subsequent metastatic progression, it is mostly recognized for regulating breast 
CSCs (119). Post chemotherapy administration in a TNBC setting, elevations in the TGF-  
signaling was observed (103). Further, the exposure of several TNBC cell lines to TGF-  
promoted EMT and the acquisition of CSC properties, including chemoresistance (120).  
 
5.7.5   Wn / -Catenin Pathway  
Wnt signaling is predominantly associated with tumor initiation, stemness, and 
metastatic dissemination (121). Several studies have highlighted the pivotal role pla ed b  Wnt/ -
catenin signaling in promoting the tumorigenic behavior associated with the TNBC subtype, For 
instance, TNBC patients with aberrant Wnt/ -catenin signaling were reported to be more 
susceptible to metastatic progression, especially to the brain and lung (122). In another seminal 
study, the Wnt signaling was identified to be vital for development, enhanced proliferation, 
increased migration, and chemotherapy resistance in TNBCs (123). Further, -catenin was 
demonstrated to have a synergistic effect with Nek2B on chemotherapy resistance in TNBC (124). 
 21 
Other constituents of the Wnt/ -catenin pathway, such as FZD-8 (a member of the Frizzled 
receptor family) was overexpressed in TNBC and linked to TNBC chemoresistance following 
neoadjuvant chemotherapy (125).  
 
5.8  Receptor Tyrosine Kinases 
The PAM and JAK/STAT signaling pathways are employed by numerous growth 
factors to mediate tumorigenesis. The upstream regulators of these pathways, namely the insulin-
like growth factor-1 receptor (IGF-1R) and EGFR, are often implicated in TNBC 
chemoresistance. EGFR expression is markedly higher in TNBCs, making it a prominent TNBC 
hallmark. Several studies have confirmed the correlation between EGFR amplification and 
expression with worse outcome in TNBC (126, 127). Via the regulation of ABCG-2 expression 
and function, the EGFR pathway is observed to promote chemoresistance in TNBC cell line and 
xenograft models (128). IGF-1R is a transmembrane receptor overexpressed in TNBCs and is 
frequently associated with poor survival (129). Insulin-like growth factors (IGFs) bind to their 
receptors, activate the downstream signaling cascade to promote chemoresistance evolution via  
ABC transporter expression, and apoptosis inhibition (130). Through its interaction with the 
Wnt/ -catenin pathway, IGF-1 enhances CSC growth and self-renewal potential (131). 
 
6. Tumor-Targeting Peptides 
The efficacy of most anti-cancer agents is often hindered by its inability to target, 
penetrate cellular membranes, and eventually localize within the tumor. Unlike standard 
chemotherapeutic agents that induce non-specific cytotoxicity, targeted therapies are often 
cytostatic. Their deliberate interaction with molecular targets  e pressed on the cancer cell 
surface inhibits cancer growth and progression (132). Targeted therapies like nanoparticles or 
antibodies possess a high molecular weight (MW), high affinity, and low diffusion coefficient 
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that impede tumor penetrability (133). On the other hand, smaller MW entities like peptides offer 
fundamental advantages, including easy synthesis, higher cell membrane penetration, and lesser 
immunogenicity (134).  
Tumor-targeting peptides (TTPs) are two-dimensional linear chain amino acid 
sequences (135), modified to either directly target cancer cell surface receptors or act as 
chaperones delivering cytotoxic drugs to the TME, tumor vasculature, and cancer cells. Targeting 
and concentrating these peptides to specific cancer tissue components is achieved via tumor-
specific biomarkers. TTPs can be coupled with either cargo or an apoptotic domain. The homing 
domain can be identified through antibody-based screens, bio-panning of phage-displayed peptide 
libraries, identified in silico using random generation algorithms, or through imitation of protein 
fragments known to bind to the receptor of interest (135).   
 
6.1  Phage Display Screening for the Isolation of Tumor-Targeting Peptides 
In 1985, Nobel laureate George Smith demonstrated that filamentous phages could be 
genetically modified to display peptides as fusions on the virus capsid protein (136). This opened 
the possibility of isolating phage-displayed peptides by selecting for those with the highest 
binding affinity to the desired target. As shown in Figure 2. below, The multivalent display of 
foreign polypeptides is achieved by cloning the peptide encoding combinatorial DNA sequences 
into the M13 phage s pIII or pVIII gene. Each phage-displayed peptide is designed as a linear 
chain of variable random amino acid residues (Xn, 6  n  12), resulting in the generation of phage-
displayed peptide libraries with complexities up to a 1013 magnitude.  To reduce conformers and 
improve affinity, the random sequences are enclosed within two cysteine residues to generate 
cysteine-to-cysteine disulfide cyclized phage-peptide libraries (137).  
The isolation of phage-displayed peptides homing to the target of interest is carried out 
via an affinity selection process, alternatively known as bio-panning. Homogenous in situ phage 
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library bio-panning using immobilized antigens can be used to isolate peptides with high affinity 
and specificity (138). However, to facilitate the identification of peptides that mimic naturally 
occurring receptor ligands or target heterogeneous environmental conditions, screens were 




Figure 2. A diagrammatic representation of M13 bacteriophage. Each bacteriophage is 1,000 
nm in length and 5 nm wide. The peptides are displayed as fusions on the pIII minor coat protein. 
 
6.2  Tumor-Targeting Peptides Specific to the TME 
Owing to its indispensable role in carcinogenesis, the TME serves as an alternative 
target for future therapies. Due to their low production cost, high specificity, and tumor 
penetrability, there has been a renewed interest in using phage display technology to identify 
peptides that efficiently target the TME. The findings below highlight some TTPs targeting 
various stromal constituents of the TME.  
 
6.2.1 Peptides Targeting Tumor Vasculature 
The tumor vasculature, with its consistently high angiogenic marker (i.e., VEGF 
receptor (VEGFR) and integrins) e pression, pronounced h po ic regions, leak  nature, and 
pivotal role in tumorigenesis, serves as an attractive therapeutic target.  A prominent example of 
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a tumor vasculature specific therap  is the RGD  peptide. Isolated using in vivo phage display 
technology in prostate tumor-bearing mice, the cyclic RGD peptide (sequence: CDCRGDCFC) 
was identified to bind with Ev-3 and Ev-5 integrins over-expressed on tumor blood vessels 
(143, 144). Subsequently, another pioneering study by Arap and colleagues led to the discovery 
of the NGR  motif bearing c clic peptides (sequence: CNRGC) that targeted tumor vasculature 
in melanoma, breast carcinoma and Kaposi s sarcoma (145). This peptide homed to the 
aminopeptidase N (APN/CD13) receptors detected in tumor vasculature (146). 
 
6.2.2 Peptides targeting Extra-Cellular Matrix  
The extracellular matrix (ECM) is composed of immensely diverse components, 
including fibronectins, tenascin C (TNC), collagen, and connective tissue growth factor, to name 
a few. Tumor-associated fibronectin (TAF) plays a vital role in promoting cancer cell survival, 
proliferation, invasiveness, and metastatic dissemination (147). During tumor driven ECM 
remodeling, TAF undergoes alternative splicing, which results in extra domains A and B (EDA 
and EDB). Through in situ phage library bio-panning, an EDB binding scaffold-like peptide 
named APTEDB was identified (138).  This peptide was further modified to a targeting ligand 
that could be conjugated with anti-cancer drugs to reduce systemic toxicity, deliver cargo, 
including siRNA, oligonucleotides, and imaging probes (148, 149).  
The TNC glycoprotein mediates the assembly of other ECM molecules and plays a part 
in mediating cell adhesion, permeation, migration, and differentiation. TNC is specifically 
associated with several solid tumor malignancies, including breast, colon, and oral cavity (150). 
This led to the isolation of a TNC targeting peptide (sequence: FHKHKSPALSPV) that 
selectively bound to TNC in both xenograft mouse tissues and patient tumors and acted through 
the reduction of  TNC-induced cell rounding and migration (138). More recently, Yeow and 
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collaborators ingeniously tackled tumor ECM targeting by conducting the first three rounds of 
bio-panning in MatrigelTM in vitro and the last round in vivo. Following the four rounds, a 
disulfide cyclized peptide (sequence: CSGRRSSKC) that exclusively homed to laminin-nidogen 
receptor complexes of the ECM was isolated (151).  
 
6.2.3 Peptides targeting Matrix Metalloproteases 
Abrogated ECM remodeling triggers the release of biophysical and biochemical cues 
that set the events of neoplastic evolution in motion. MMPs are one of the most studied ECM 
remodeling enzymes due to their up-regulation in the TME and roles in angiogenesis regulation, 
tumor cell migration, and invasion. Despite being secreted proteins, MMP-2 and MMP-9 mediate 
phage homing by binding to integrins expressed by tumor vasculature. Based on this principle, 
peptides targeting the gelatinase members of the MMP family (sequences: CRRHWGFEFC and 
CTTHWVGLMS) and subsequently inhibiting MMP-2 and MMP-9 activity were discovered 
(152). In 2019, Bicycle therapeutics pioneered in vitro phage display technology to develop 
BT1718, a peptide-drug conjugate targeting the ECM enzyme MMP-14. This drug is currently 
undergoing Phase I clinical trials in patients with advanced solid tumors (133).  
 
6.2.4 Peptides targeting Cancer-Associated Fibroblasts  
Within the TME, cancer-associated fibroblasts (CAFs) are often found to reside within 
the proximity of tumor cells. Unlike tumor cells that express diverse cell surface markers, CAFs 
predominantly overexpress specific proteins, including fibroblast-activated protein-alpha (FAP-
) and alpha-smooth muscle actin ( -SMA) (153). Thus, CAF targeting may be an alternative 
strategy to improve anti-tumor efficacy. In a seminal study combining in vivo phage display and 
the PHASTpep software, two peptides (sequences: APPIMSV and HTTIPKV) targeting CAFs 
were identified (154). The peptides selectivel  bound to onl  -SMA positive pancreatic CAFs 
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in mice. Several studies have reported that the CAFs within the TME of colon, breast, and prostate 
were carcinomas dependent on the urokinase plasminogen activator (uPA) receptor signaling axis 
to mediate the events implicated in early tumor development. This prompted the isolation of a 
peptide (sequence: LWXXAr (Ar = Y, W, F, H) XFXXYLW) that acted as a potent antagonist 
against the uPA receptor (155).  
 
6.2.5 Peptides targeting Tumor-Associated Macrophages 
Derived from circulating monocytes within the TME, tumor-associated macrophages 
(TAMs) are specified as a separate myeloid population of the TME. Tumor-secreted cytokines 
(IL-4 or M-CSF) mediate macrophage polarization into anti-inflammatory M2-skewed TAMs that 
promote tumor angiogenesis, immunosuppression, and neoplastic transformation (156). M2-
skewed TAMs traverse the TME s comple  milieu with either the aid of collagen-interacting 
proteins, including collagenases, MMP-9, and mannose receptors (CD206/MRC-1) or through 
tumor vasculature via VEGF secretion (157). The in vitro phage-displayed peptide library bio-
panning performed by Cieslewicz and collaborators yielded M2Pep (sequence: 
YEQDPWGVKWWY), which selectively targeted M2-skewed mouse TAMs in mouse colon 
carcinoma tumors (158). To improve its affinity, the authors synthesized a tetravalent version of 
the peptide, which coupled was to a C-terminal cysteine on a maleimide scaffold. This peptide 
was then conjugated with a pro-apoptotic domain, which augmented its toxicity towards M2 
TAMs (158). In 2017, in vivo phage display in metastatic breast cancer-bearing mice led to the 
identification of a CD206-binding peptide termed mUNO (159). The internalization of mUNO by 
M2 TAMs was mediated through the minimal binding CSPGAK sequence motif present in all 
CD206-binding collagens. Interestingly, the mUNO peptide also binds to human recombinant 
CD206, indicating future therapeutic potential in cancer patients (159).  
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6.3 Tumor-Targeting Peptides Specific to Overexpressed Tumor Receptors 
Post administration, anti-cancer therapies often modulate the expression of cell-surface 
receptors implicated in carcinogenesis. Agents such as antibodies, peptides, or small molecule 
inhibitors, can serve to inhibit the receptor s downstream activit  b  directl  binding to them, 
thus halting cancer progression. In the following section, a few prominently over-expressed 
receptors used in cancer cell-specific targeting have been discussed.   
 
6.3.1 Peptides Targeting EGFR  
Through its complex signaling cascade, EGFR modulates several events implicated in 
carcinogenesis, including cancer cell survival, proliferation, differentiation, adhesion, and 
migration. In 2014, Wang, Zho, and Joshi were awarded an international patent (Patent No. 
WO2016029125A1) for 17 EGFR-specific peptides identified through in situ phage library 
screening of Ph.D.-7 heptapeptide and Ph.D.-12 decapeptide random libraries from New England 
Biolabs (160). Li and colleagues are credited with isolating the prominent GE11 peptide, 
internalized preferentially by both EGFR overexpressing cancer cells in vitro and tumor 
xenografts in vivo (161). Another group identified two short peptides (sequences: SYPIPDT and 
HTSDQTN) via an in vitro cell-based subtractive bio-panning approach in EGFR overexpressing 
A-431 cells. These peptides effectively inhibited EGF-induced phosphorylation of EGFR in a 
concentration-dependent manner (162).  
 
6.3.2 Peptides Targeting VEGFR  
VEGFR belongs to the VEGFR receptor family (VEGFR 1, 2, 3, and neuropilin 1). The 
overexpression of VEGFR and its cognate VEGF ligand is observed in several malignancies (163-
165). To identify novel ligands specific to VEGFR-3, Qin and coworkers used phage-displayed 
peptide library screening to isolate the peptide P1 (sequence: CSDXXHXWC, where X is any 
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amino acid) which bound to all VEGFR-3 positive tumor cells with a high degree specificity 
(166). In another study, using the novel BRASIL method, Giordano and colleagues sorted for cell-
surface binding peptides based on differential centrifugation. They isolated 21 phage-displayed 
peptide clones that bound to VEGF-stimulated HUVEC cells (167).  
 
6.3.3 Peptides Targeting Interleukin 11 Alpha Receptor  
Upon up-regulated expression, IL-11 confers several tumor intrinsic hallmarks  to 
neoplastic cells. An integral member of the IL-6 family of cytokines, it dictates the progression 
of the metastatic cascade via downstream JAK/ STAT-3 signaling pathway activation (168). 
Pasqualini and colleagues first explored the potential of using IL-11 R as an anti-tumor target via 
in vivo bio-panning of a 7-mer library in chemotherapy-refractory B cell malignancy bearing 
patient (142). In a companion study, the authors isolated a phage clone (sequence: 
CGRRAGGSC) that bound to IL-11 R overexpressed in the prostate, which was further validated 
in prostate tumor-bearing mice and human prostate cancer tissue samples (169).When conjugated 
with a pro-apoptotic moiety, this peptide also demonstrated acute cytotoxicity on cultured prostate 
cancer cells (165).  
 
6.3.4 Peptides Targeting Folate Receptor Alpha 
Folate receptor-alpha (FR ) overe pression often co-relates with high tumor grade, 
stage, malignancy, and aggressiveness (170), thus serving as a potential target for tumor therapy 
and diagnosis. Xing and coworkers isolated the FR  specific C7 peptide (sequence: 
MHTAPGWGYRLS) by screening a Ph.D.-12 phage library displaying random dodecapeptides 
in an ovarian cancer mouse model. The C7 peptide was further validated outside the phage 
context, through in vivo phage homing experiments and fluorescence imaging (171).  
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6.3.5 Peptides Targeting PDGFR beta  
A transmembrane glycoprotein in the receptor tyrosine kinase family, PDGFR-beta 
(PDGFR ), is implicated in cancer cell proliferation, differentiation, and development (172). 
Owing to its upregulation in a variety of solid tumors, this receptor represents an attractive target 
in the treatment and molecular imaging of oncological diseases. PDGFR-P1 (sequence: 
IPLPPPSRPFFKY-NH2) is a s nthetic peptide designed to bind to PDGFR  overe pressing cells 
in vitro. In vivo biodistribution studies in the BxPC3 tumor mouse model revealed a high 
accumulation of PDGFR-P1peptide in BxPC3 tumors than in normal organs (173).  
 
6.4 Design of Tumor-Specific Hunter-Killer Peptides 
A unique feature of anti-microbial peptides (AMPs) is the amphipathic -helix, which 
grants its membrane permeabilization and resultant cytotoxic potential. The synthetic 
(KLAKLAK)2 moiety, which mimics AMP features and demonstrates significant anti-microbial 
activity, was generated based on this principle. The (KLAKLAK)2 moiety is highly selective to 
the anionic membranes of prokaryotes and is poorly permeabilized by eukaryotic plasma 
membranes. To promote tumor cell internalization, the (KLAKLAK)2 moiety is fused with TTPs 
to generate hunter-killer peptides that act through mitochondrial disruption (174). For instance, 
the hunter-killer R7- (KLAKLAK)2 peptide consisting of the homing domain (R7 or RRRRRRR) 
shows increased cellular uptake and efficient apoptosis in several tumor cell lines and human 
xenografts (175). Along the same principles, the NH2-terminus of TCTP (human translationally 
controlled tumor protein) was fused to the (KLAKLAK)2 moiety resulting in the hunter-killer 
TCTP-(KLAKLAK)2 peptide. This peptide promoted the regression of lung carcinomas implanted 
in mice (176). Our own group has generated a proteolysis-resistant targeted hunter-killer peptide 
D-WAT. This peptide is composed of a cyclic domain CSWKYWFGEC homing to adipose 
 30 
stromal cells and pro-apoptotic domain (KFAKFAK)2 (177). The addition of the (KFAKFAK)2 
moiety was observed to improve the cytoablative properties of D-WAT. The above examples 
underscore the potential use of TTPs fused to a cytotoxic peptide, to produce a highly efficacious, 




























1. Knowledge Gap 
An insurmountable challenge encountered in the clinical management of TNBCs is metastatic 
progression. Metastatic dissemination continues to be a major perpetrator of TNBC patient 
mortality. Owing to the unresponsiveness of TNBCs to hormone therapy, chemotherapy remains 
a mainstay in mTNBC treatment. Despite chemotherapy eliciting a brief response in the tumors, 
drug resistance gradually develops. Several studies suggest that chemotherapy appears to select 
for cells with CSC properties that drive cancer toward more aggressive stages (178). There are no 
bio-markers specific to chemoresistant metastatic tumor cells. Moreover, there is a dearth of drugs 
available to selectively target them. Therefore, it is imperative to develop novel targeted therapies 
to ablate these stubborn tumor cell populations. The isolation and development of peptides 
selectively targeting these chemoresistant metastatic tumor cells would be pivotal for cancer 
medicine, as they would enable targeting the mortality-responsible cell population with minimal 
side effects. This rationale encouraged us to formulate the following hypothesis.  
 
2. Hypothesis 
Metastatic chemoresistant TNBC cells display novel cell surface biomarkers, which can be used 
in the identification of new compounds homing to these unique cell populations and specifically 
ablating them. 
 
3. Aims and Experimental Approach 
Aim 1: Identify phage-displayed peptides homing to chemoresistant metastatic tumor cells.  
Experimental Approach 
x Perform an in vivo phage-displayed peptide library screen in a spontaneous TNBC lung 
metastasis model to isolate phage-displayed peptide candidates homing to metastatic tumor 
cells.  
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x Compare the homing of the phage-displayed peptide candidates between vehicle control and 
cisplatin-treated in vitro and in vivo models. 
x Identify the most enriched breast lung metastasis peptide (BLMP) candidate.  
 
Aim 2: Conversion of phage-displayed peptides into hunter-killer peptides that ablate metastatic 
tumor cells in vitro and in vivo 
Experimental Approach 
x Validation of the chemically synthesized hunter-killer peptide candidates in vitro.  
x In vivo studies to validate the ability of hunter-killer peptides to ablate TNBC pulmonary 
metastases. 
 
4. Graphical Abstract 
 
 























1. Cell Lines and Cell Culture 
Murine fibroblast 3T3L1 (ATCC® CRL-1658 ), murine melanoma B16-F10 
(ATCC® CRL-6475 ), murine mammary breast adenocarcinoma E0771 (ATCC® CRL-2755 ) cell 
lines were obtained from the ATCC (Manassas, VA). The human mammary adenocarcinoma 
MDA-MB-231 cell line was kindl  provided b  Dr. Wenliang Li s lab (IMM-UTHealth, Houston, 
TX). The mammary adenocarcinoma murine 4T1 cell line with dual luciferase and mCherry 
expression (4T1 - Luc+ mCherry+) was kindl  provided b  Dr. Sendurai A. Mani s lab (MDACC, 
Houston, TX). The murine mCherry labeled 4T1.2 (4T1.2 - mCherry+) breast tumor cells (derived 
from spontaneous adenocarcinoma in a Balb/cfC3H mouse) was kindly provided by Dr. Naoto 
Ueno s lab (MDACC, Houston, TX). It s cisplatin-resistant cell lineage, 4T1.2/CTX, was 
generated with a biweekly treatment of cisplatin (Tocris Biosciences, Minneapolis, MN; 
180ng/mL) to maintain consistent drug resistance. The cell lines were cultured in DMEM media 
(Hyclone Laboratories Inc., Logan, UT) supplemented with 1% penicillin-streptomycin (Gibco) 
and 10% FBS (Atlas Biologicals, Fort Collins, CO). All cell lines were cultured on plastic plates 
maintained at 37ºC and 5% CO2. Sub-culturing was performed at 70% cell confluency. Adherent 
cells were washed with 1X PBS (Phosphate-Buffered Saline) solution (Fisher Scientific, 
Waltham, MA) and detached with 0.25% trypsin-EDTA (Gibco) and then sub-cultured.  
 
2. Murine Model of Experimental Lung Metastasis 
All mouse experiments were performed in accordance with the bioethical principles 
adopted by the Institutional Animal Care and Use Committees of UTHealth and MDACC. Female 
C57BL/6 mice (Jackson, Bar Harbor, ME) were aged eight weeks prior to experimental 
manipulation. The mice were anesthetized using tribromoethanol (150mg/kg) administered 
through intraperitoneal injections. Murine melanoma B16-F10 cells (100,000 cells suspended in 
100 l DMEM) were injected into the mice intravenousl . Following this procedure, the mice were 
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kept warm under a heat lamp and monitored until recovery. Upon resuming mobility, the mice 
were housed back in their cages. Ten days post tumor implantation; the mice were randomized 
into vehicle and chemotherapy-treated cohorts. The mice were administered either vehicle (1X 
PBS solution) or cisplatin (Tocris Biosciences; 2.5mg/kg) retro-orbitally once a week for three 
weeks. Upon exhibiting distress, the mice were euthanized, and their organs (brain, spleen, liver, 
kidney, and lung) surgically resected. After excision, the tissues were fixed in 10% neutral-
buffered formalin (Thermo Fisher Scientific, Waltham, MA) for histopathological analysis. 
 
3. Orthotopic Murine Model of Spontaneous Lung Metastasis  
Female Balb/c mice (stock 000651, Jackson) were six weeks old at the start of the 
experiment. Prior to cell injection, the animals were anesthetized through 2-4% isoflurane (Fisher 
Scientific) inhalation. The site of tumor implantation was prepped with 70% ethanol solution and 
shaved with hair clippers. 4T1-Luc+ mCherry+ (20,000 cells suspended in 20 l DMEM) were 
subcutaneously injected into the mammary gland of the syngeneic Balb/c mice. The correct 
injection of cancer cells was validated through the visual confirmation of fat pad swelling. Once 
palpable, the growing primary tumors were measured biweekly with calipers with tumor volume 
calculated using the (length x width2)/2 formula. After the tumor volumes reached ~ 200mm3, the 
mice were randomized into two cohorts, vehicle and chemotherapy-treated, respectively. The 
mice were administered either vehicle (1X PBS) or cisplatin (Tocris Biosciences; 2.5mg/kg) retro-
orbitally once a week for three weeks. Multiple row t-tests were performed to account for the 
differences observed in tumor volume between the two groups. Upon exhibiting adverse effects 
such as labored breathing or ulcerated tumors, the mice were humanely euthanized. This was 
followed by surgical resection of organs (brain, spleen, liver, kidney, and lung) and tumors. After 
excision, the tissues were then fixed in 10% neutral-buffered formalin.  
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4. Non-Invasive Bioluminescence Imaging to Monitor Metastatic Progression In Vivo 
4T1 Pulmonary metastases bearing mice were injected intraperitoneally with D-
luciferin (Promega, Madison, WI; 150 mg/kg) and anestheti ed 9 minutes before the peak 
luciferin uptake time (according to manufacturer s procedures) with 5% isoflurane. At the optimal 
imaging time, the mice were transferred to the imaging chamber (IVIS SPECTRUM, PerkinElmer 
Inc., Boston, MA) with their mouths and noses firmly set within the anesthetic tubing maintained 
at 2% isoflurane until BLI was completed. In the fat pad spontaneous metastasis model, weekly in 
vivo bioluminescence imaging BLI was initiated at the time of tumor implantation. Due to 
differences in tumor burden, an autoexposure (1 second 1.5 minutes) was used for each mouse to 
account for any variabilities in the bioluminescence signal. BLI imaging of the primary tumors 
was performed in the following setting: emission filter: open, f/stop: 1, binning: medium, 
1 scan/minute, e posure time: 1 15 second. While imaging metastatic lesions in the thoracic 
cavity, bleed-over from the implantation site was avoided by masking the primary tumor/injection 
site with an X-ray sheet encased in aluminum foil. Metastatic burden was then evaluated by 
drawing a standard circular ROI (same size over all the time points) over the lung region. 
Luminescence was expressed as photons/sec/ROI minus background luminescence for a region 
of similar size. Bioluminescent signals were quantified to radiance intensity using Living Image 
3.0 (Caliper Life Sciences, Almeda, CA).  
 
5. In-situ Lung Perfusion and Fixation 
The animals bearing pulmonary metastases were anesthetized using tribromoethanol 
(150mg/kg) administered through intraperitoneal injections. When the mice's reflexes were no 
longer observed, the mice were splayed on a Styrofoam board with their limbs secured in position 
with push pins. The fur was wet with 70% ethanol to slick the hairs down. The chest cavity was 
opened with surgical scissors, and a V  shaped incision was made from the sternum ape  through 
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the ribs to the upper left and right shoulder. This was followed by cutting the vena cava caudalis 
underneath the liver. Using a 20 mL syringe equipped with a 21G needle, 15mL 1X PBS was 
slowly injected into the right ventricle of the beating heart until the lungs were inflated, and the 
heart stopped beating (asystole). Using forceps, the heart and lungs were pulled out as one unit 
by firmly grasping the lung hilus directly above the heart. The heart was separated from the lungs 
carefully by pulling the heart with forceps, and by transecting connective tissue ligaments and 
blood vessels. The lungs were then fixed in 10% neutral-buffered formalin. 
 
6. Enumerating Pulmonary Metastasis in Mice 
The lungs bearing pulmonary metastases were fixed in 10% neutral-buffered formalin 
until the metastatic nodules were bleached to amelanotic gray/white nodules. Using forceps, the 
fixed lungs were pried apart into individual lobes. At 10X magnification, the tumor nodules on 
each lobe were enumerated blindly beneath a dissecting microscope. For consistency between the 
mice, the foci number on the lobe surface was first counted, and then the lobe was inverted. Doing 
each of the four lobes individually allowed for more accuracy in counting. The average number 
of nodules for all mice within both treatment groups was determined.  
 
7. In Vivo Phage-Peptide Library Bio-panning for Lung Metastases Targeting Peptides 
7.1     Round 1 of In Vivo Phage-Displayed Peptide Library Bio-panning  
Phage-displayed peptides were selected from  fUSE5 phage-peptide libraries, which 
were kindly provided by Dr. Erkki Koivunen (University of Helsinki, Finland). Library 
amplification was conducted as described previously (179). Phage transducing units (TU) were 
determined through titration with K91 Escherichia coli. A mouse bearing 4T1 pulmonary 
metastases from the chemotherapy-treated cohort was anesthetized through 2-4 % isoflurane 
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inhalation. A 1010 TU mixture of cyclic CX7C and CX8C (C: disulfide-bonded cysteines; X: any 
amino acid) phage-displayed peptide libraries suspended in 1X PBS was injected intravenously 
and allowed to circulate for 3 hours. The mouse was perfused with 15mL of 1X PBS solution as 
described previously in Section 5,  to facilitate phage elimination from normal vasculature and 
other non-lung metastasis specific antigens. The mouse was euthanized, and its organs (lungs, 
liver, kidney, primary tumors, brain, and spleen) resected. 
 
7.2     Lung Tissue Digestion for Cell Isolation  
Lungs bearing 4T1 pulmonary metastases were minced manually and digested with 
collagenase (Worthington, Franklin County, OH; 250 U/ml in PBS) and dispase (Roche, 
Indianapolis, IN; 2.4U/ml in PBS) for 30 minutes at 37ºC with intermittent shaking. Enzymatic 
digestion was neutralized with growth media (DMEM with 2% FBS). The samples were 
centrifuged at 300 x g for 8 minutes. The supernatant lysate was discarded, and the cell pellet 
resuspended in growth media (DMEM with 5% FBS). The samples were passed through a 70Pm 
cell strainer (Fisher Scientific), washed once in growth media (DMEM with 2% FBS), and 
incubated in Red Blood Cell Lysis buffer (BD Pharmigen, San Jose, CA) for 15 minutes at room 
temperature in the dark. After centrifugation at 200 x g for 5 minutes, the supernatant was 
carefully aspirated, and the pellet was resuspended in growth media (DMEM with 2mM EDTA 
and protease inhibitors; Thermo Fisher Scientific). The samples were transferred into 35Pm 
strainer-capped flow cytometry tubes for flow cytometric analysis.  
 
7.3     FACS Recovery of Pulmonary Metastatic 4T1-Luc+mCherry+ Tumor Cells  
For fluorescence-activated cell sorting (FACS) analysis of the prepared single-cell 
suspensions of mouse lung tissue samples, the cells were prepared at a concentration of 1 million 
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cells/ mL and pre-gated to exclude non-viable cells, tissue debris and cell clumps. Lung cells 
recovered from a healthy tumor-free mouse were used as gating control. 4T1-Luc+ mCherry+ 
tumor cells from pulmonary metastases were recovered based on gating with mCherry 
fluorescence. 50,000 mCherry+ singlets were analyzed per sample with a FACSAria II /FlowJo 
software (BD Biosciences, San Jose, CA).  
 
7.4     Recovery of Phage-Displayed Peptides from Metastatic Tumor Cells  
The FACS sorted 4T1-Luc+ mCherry+ tumor cells recovered from pulmonary 
metastases were resuspended in growth media (DMEM with 10% FBS). The cell suspension was 
homogenized in 1mL glass douncers (Sigma Aldrich, St. Louis, MO) to rupture the cells and 
extravasate the internalized phage-displayed peptides. Following centrifugation at 14,000 rpm, 
the bound phage was eluted, and used to infect K91 E. coli host cells. Bacteriophage was isolated 
from K91 E. coli by polyethylene glycol (PEG) precipitation, amplified, purified, and 
resuspended in PBS as described previously (179). Through K91 E. coli infection, bacteriophage 
enumeration was performed using the double-layer agar technique in LB agar plates (20g/L LB 
Agar, 0.01g/L Tetracycline and 0.05g/L Kanamycin; Thermo Fisher Scientific). 
 
7.5     Enrichment of Peptides in Rounds 2 and 3 of In Vivo Bio-panning 
1010 TU of phage recovered from Round 1 of selection was used as input phage for the 
next round of in vivo selection and were recovered after 3 hours of circulation as described from 
Sections 7.1 to 7.4. Between each round, the foreign DNA inserts and encoded peptide sequences 
were determined for the top 10 most enriched phage clones to gauge the selection process and the 
absence of contamination, as described in Section 7.6. These phage-displayed peptide clones were 
bulk-amplified and subsequently pooled as described for the next round of in vivo selection (179). 
A total of three rounds of selection was performed.  
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7.6   PCR, DNA Sequencing and Insert Analysis  
Following the final round of in vivo selection, the eluted phages were used to infect 
K91 E. coli host cells. The bacteriophage-infected K91 host cells were serially diluted in LB Broth 
(25g/L LB Broth, 0.01g/L Tetracycline, and 0.05g/L Kanamycin; Thermo Fisher Scientific). 
1000-fold dilutions were plated using the double-layer agar technique in LB agar plates and 
incubated for 12 hours at 37 ºC to form plaques. Individual clones were isolated using sterile 
toothpicks and stored in 50% glycerol (Fisher Scientific) stocks in a 96 well format for future 
amplification. The insert size of each phage clone was analyzed by PCR. Insertless Fd-Tet and D-
WAT phages were used as negative and positive controls. The PCR reactions were carried out in 
a 10PL reaction volume containing a single colony of phage infected K91 E. coli, 5PL Azura 2X 
Taq Mix (Azura Genomics Inc., Raynham, MA), 2PL of the forward primer 5 -
TTAACTCCCTGCAAGCCTCA-3  and 2PL of the reverse primer                                                               
5 -CCCTCATAGTTAGCGTAAGC-3  and 1PL PCR grade water (Thermo Fisher Scientific). 
The PCR reactions were performed using a Mastercycler Pro Thermal Cycler (Eppendorf, 
Hauppauge, MA) at the following conditions: 25 cycles of denaturation at 94ºC for 10 seconds; 
annealing at 60ºC for 30 seconds; and extension at 72ºC for 60 seconds. The product size was 
assessed by 1.8% agarose gel electrophoresis in 1X TAE buffer (Tris-Acetate EDTA Buffer) at 
80 volts for 40 minutes. PCR product clean up and DNA sequencing to ascertain the displayed 
foreign peptide of each phage was carried out by Epoch Life Sciences (Houston, TX). Sanger 
sequencing was done using the M13-pIII sequencing primer                                                                                                                  
5 -TTAACTCCCTGCAAGCCTCA-3 . The automated Sanger sequences were represented as 
chromatograms, analyzed using the Chromas software (Technelysium Pty Ltd, Queensland, 
Australia). The amino acid sequences of the fused peptide inserts were deduced from the DNA 
sequence using the ExPASy Bioinformatics Resource Portal (SIB, University of Lausanne, 
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Switzerland). Multiple sequence alignment of the selected phage-displayed BLMP clones from 
each round was performed using Clustal  (Omega) software (EMBL-EBI, Cambridgeshire, UK). 
The sequences were then analyzed by the BLAST algorithm (NLM, Bethesda, MD) for homology 
with known or putative cancer correlations, identify the presence of consensus motifs,  and to 
define clones for further analyses.  
 
8. In Vitro Phage-Displayed Peptide Homing Validation  
8.1    Phage-Displayed Peptide Internalization Assay  
The relative specificity of phage-displayed BLMP clones was assessed individually in 
vitro. Cells were grown to 60% confluency in a 24-well tissue culture plate (Costar, Fisher 
Scientific) overnight at  37ºC  in growth medium (DMEM with 10% FBS). The growth media 
was removed and a new medium (DMEM with 2% FBS) with either 109 TU of BLMP clones or 
insertless phage separately and incubated at 37ºC for 5 hours. Insertless Fd-Tet phage was used 
as a negative control. The adherent cells were washed thrice with 1X PBS solution, detached with 
0.25% trypsin-EDTA, and resuspended in 2mL growth media (DMEM with 10% FBS). Cell count 
for each sample was determined individually using a hemocytometer. The internalized BLMP 
clones were recovered by rupturing the cell membranes using glass douncers. The individual 
phage-displayed BLMP clone samples were centrifuged at 14,000rpm for 5 minutes. The cell 
lysate of each sample containing the extravasated BLMP clones was used to infect K91 E. coli. 
The bacteriophage infected K91 host cells were serially diluted in LB Broth. 1000-fold dilutions 
were plated using the double-layer agar technique in LB agar plates and incubated for 12 hours at 
37ºC to form plaques. The homing specificity of each BLMP clone was quantified as a ratio of 




8.2    Phage-Displayed Peptide Internalization Validation by Immunofluorescence 
Cells were grown to 60% confluency in a 24-well tissue culture plate (Costar, Fisher 
Scientific) overnight at  37ºC  in growth medium (DMEM with 10% FBS). The growth media 
was removed and 0.2L  new medium (DMEM with 2% FBS) with either 109 TU of BLMP clones 
or insertless phage separately and incubated at 37ºC for 5 hours. Insertless Fd-Tet phage was used 
as a negative control. The adherent cells were washed thrice with 1X PBS solution to remove non-
specific unbound phage. The cells and bound phage were fixed by the addition of 4% 
formaldehyde in PBS solution and blocked with a Serum-free protein block (Pierce, Thermo 
Fisher Scientific) for 1 hour at room temperature. The internalization of phage by the cells was 
probed by the addition of a rabbit polyclonal anti-Fd bacteriophage primary antibody (Sigma 
Aldrich; 1:500) incubated at 4 °C for 12 hours.  The wells were extensively washed with TBS 
(PBS/0.05% Tween-20, Thermo Fisher Scientific) three times before being incubated with 
donkey anti-rabbit Cy3-conjugated (Jackson ImmunoResearch Laboratories. INC, West Grove, 
PA; 1:300) Secondary IgG for one hour in the dark at room temperature. Nuclei were stained with 
Hoechst 33258 (Invitrogen, Grand Island, NY). Fluorescence images were acquired with a Nikon 
Eclipse TE2000E Widefield Fluorescence Microscope (Nikon Instruments Inc, Melville, NY). 
 
9. In Vivo Phage-Displayed Peptide Homing Validation  
Individual phage-displayed BLMP clones were injected into vehicle and cisplatin-
treated (2.5mg/kg) treated spontaneous and experimental metastasis murine models. The BLMP 
clones were allowed to circulate for three hours, after which the mice were anesthetized using 
tribromoethanol (150mg/kg) administered through intraperitoneal injections. Lung perfusion, 
organ resection, and subsequent fixation were performed as described in Sections 2, 3, and 5. The 
tissues harvested from the mice were embedded in paraffin. Slides with sections of formalin-fixed 
tissues and tumors embedded in paraffin were deparaffinized and rehydrated as described (180). 
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Antigen retrieval was performed by heating the slides in 10mM sodium citrate buffer (Pierce, 
Thermo Fisher Scientific) at 95°C for 20 minutes and slowly cooled to room temperature for 
another 20 minutes. The tissue sections were blocked with a Serum-free protein block solution 
and incubated at room temperature for 2 hours. Primary antibodies (4°C, 12 16 hours) and 
secondary antibodies (RT, 1 hour) were applied in TBS. The following primary antibodies were 
used: rabbit anti-Fd (Sigma-Aldrich; 1:500), goat anti-mouse CD31 (Santa Cruz Biotechnology, 
Santa Cruz, CA, 1:150), mouse anti-E Cadherin  (BD Biosciences, San Jose, CA; 1:100), mouse 
anti-N Cadherin (BD Biosciences, San Jose, CA; 1:100) and mouse anti-Cytokeratin 
(MyBioSource, San Diego CA; 1:200). Secondary IgG used were as follows: donkey anti-mouse 
Alexa 488-conjugated (Invitrogen, 1:300) and donkey anti-rabbit Cy3-conjugated (Jackson 
ImmunoResearch Laboratories. INC; 1:300). Nuclei were stained with Hoechst 33258. 
Fluorescence images were acquired with a Nikon Eclipse TE2000E Widefield Fluorescence 
Microscope (Nikon Instruments Inc).  Hematoxylin and eosin (H&E) staining was performed by 
histology CORE (IMM-UTH, Houston, TX). Images of H&E stained tissue sections were 
obtained with Zeiss Axio Scope Brightfield Microscope (Carl Zeiss Meditec, Inc., Dublin, CA). 
 
10. Design and Synthesis of Hunter-Killer Peptides 
All hunter-killer peptides were made as proteolysis-resistant all D-amino acid  
peptides.  The apoptotic domain, a cationic amphipathic sequence (KLAKLAK)2, was linked to 
the targeting domain via an amino hexanoic acid linker (NH-(CH2)5-CO). Peptides were 
synthesized by conventional peptide chemistry, cyclized via cysteines, purified to >90% by 
HPLC, and quality controlled (mass spectroscopy). Peptide instability and proteolytic cleavage in 
vivo were addressed via L-amino acid to D-amino acid sequence conversion accompanied by 
terminal N or C- terminus blockade. Lyophilized peptide acetate salt powder was reconstituted in 
PBS solution to a concentration of 10 mmol/L, and aliquots were stored at -20ºC until dilution in 
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PBS, filtration, and use. The following hunter-killer peptides were designed and purchased from 
Celtek Bioscience (Franklin, TN):  
1. HK-BLMP7: Composed of breast lung metastasis (BLM) homing peptide BLMP7 (sequence: 
CLRHSSKIC) conjugated to apoptotic (KLAKLAK)2 domain. 
2. HK-BLMP8: Composed of BLM-homing peptide BLMP8 (sequence: CRAGVGRGC) 
conjugated to apoptotic (KLAKLAK)2 domain. 
The following peptides were designed and purchased from Ambiopharm (North Augusta, SC):  
1. D-CAN: Composed of Adipose stromal cell (ASC) homing peptide WAT7 (sequence: 
CSWKYWFGEC) conjugated to apoptotic (KLAKLAK)2 domain. 
2. (KLAKLAK)2: Composed of uncoupled lytic amphipathic sequence 
(KLAKLAKKLAKLAK).  
 
11. Biotin-labeled HK-BLMP Internalization Assay In Vitro 
HK-BLMP7 and HK-BLMP8 peptides were labeled with biotin using the Sulfo-NHS-
LC-Biotin Kit (APExBIO, Houston, TX) according to the manufacturer s guidelines. Cells were 
cultured as specified above and incubated with biotin-labeled HK-BLMP7 (30Pmoles/L) or HK-
BLMP8 (20Pmoles/L) peptides for 5 hours at 37ºC. The adherent cells were fixed and blocked, 
as described in Section 8.2. The internalization of the biotin-labeled peptide by the cells was 
probed by the addition of Streptavidin-Cy3 (Zymed, Thermo Fisher Scientific; 1:50) for one hour 
in the dark at room temperature. Nuclei were stained, and fluorescence images were acquired as 





12.  In Vitro Assay for Cell Viability 
Cells were grown to 60% confluency in 48-well tissue culture plates (Costar, Fisher 
Scientific) overnight at  37ºC  in growth medium (DMEM with 10% FBS). HK-BLMP7, HK-
BLMP8,  D-CAN, or uncoupled (KLAKLAK)2 was added to each well. Peptide concentrations 
ranging from 1 to 300 Pmoles/L were added to 0.2 mL serum-free media in each of the wells and 
incubated for at 37ºC for 8 -24 hours. Trypan blue exclusion assay and the cleaved-caspase3 assay 
was used to determine cell viability in peptide-treated cell lines.  
 
12.1  Validation of Cell Viability by Trypan-Blue Staining 
Following hunter-killer peptide treatment, live and dead cells were distinguished by 
staining with 0.4% Trypan Blue solution (MP Biomedicals, Santa Ana, CA) for 10 minutes. The 
solution was slowly decanted and replaced with 4% formaldehyde in PBS solution to fix the cells. 
The cells were imaged and analyzed with a Nikon Eclipse TE2000E Widefield Fluorescence 
Microscope (Nikon Instruments Inc.). 
 
12.2  Validation of Apoptosis induction by Cleaved-Caspase 3 Staining 
Following hunter-killer peptide treatment, cells were fixed and blocked, as described 
in Section 8.2. Cell viability was probed by the addition of primary antibody: anti-Asp175-cleaved 
Caspase3 (Cell Signaling Technology, Beverly, MA; 1:100) incubated at 4 °C for 12 hours. 
Secondary donkey anti-rabbit Cy3-conjugated (Jackson ImmunoResearch Laboratories. INC; 
1:300) (Invitrogen; 1:150) for one hour in the dark at room temperature. Nuclei were stained, and 




13. In Vivo Metastasis Ablation Study with HK-BLMP8  
Female Balb/c mice (stock 000651, Jackson) were ten weeks old at the start of the 
experiment. The mice were implanted with 4T1 breast tumors, as described in Section 3.3. Once 
the tumors were palpable, the mice were split into two cohorts (n=5). Mice in each cohort were 
administered twelve doses of either vehicle (1X PBS) or HK-BLMP8 peptide (10mg/kg) 
subcutaneously into the lower back over a period of  4 weeks. During this period, the mice were 
periodically monitored and subjected to weekly BLI to monitor and image metastatic progression. 
Upon reaching morbidity, the animals were then euthanized.  
 
14. Statistical Analysis 
Statistical analysis was carried out using GraphPad Prism 8 software (GraphPad, La 
Jolla, California). Multiple row t-tests were used to compare changes in tumor volume between 
vehicle control, cisplatin-treated, and hunter-killer peptide treated mice. Two-way Anova was 
used to compare the binding efficiency of the six BLMP clones across different cell lines. The 
Log-rank (Mantel-Cox) test was used to compare the survival probability between vehicle control 































1. Cisplatin treatment elicits no tumor response but exacerbates metastatic burden 
In order to conduct the in vivo phage-displayed peptide library screen for 
chemoresistant TNBC pulmonary metastases, the 4T1 orthotopic syngeneic murine model was 
selected. This in vivo model of spontaneous metastasis has been well characterized and has been 
used in several studies for the elucidation of the mechanisms implicated in chemoresistance 
evolution and subsequent metastatic progression (181-184). Dual-luciferase and mCherry labeled 
4T1 adenocarcinoma cells obtained from Dr. Sendurai Mani s lab, were orthotopically implanted 
into the mammary fat pad of Balb/c mice. Once the tumors reached a volume of 200mm3, the 
mice were randomized into two groups (n=20/cohort) and treated with vehicle control or 2.5mg/kg 
cisplatin retro-orbitally for three weeks. The tumor volumes were measured thrice a week until 
the mice attained morbidity. Further, metastatic progression was measured weekly using non-
invasive bioluminescence imaging until the mice succumbed to metastasis-induced mortality.  
Based on Welch s t-test analysis, no significant difference (p=0.5735) in tumor 
volumes was observed between the two groups during the treatment period (Figure. 1A). These 
observations were sustained even upon treatment completion (Figure. 1A). These results suggest 
that cisplatin administration had no effect on primary tumor growth. However, upon analysis of 
non-invasive bioluminescence images of the mice, a significant difference in metastatic burden 
was indicated between the groups (Figure. 1B). In the cisplatin-treated mouse cohort, cancer 
progression and subsequent pulmonary metastatic burden were significantly higher when 
compared to the vehicle-treated mouse cohort (Figure. 1B). These observations were further 
corroborated through pulmonary metastases nodule quantification. At the experimental endpoint, 
mice were euthanized, and their lungs subjected to PBS perfusion. The lungs were then fixed in 
formalin until the metastatic nodules were bleached to amelanotic gray/white nodules                        
(Figure. 1C). This was followed by a blind enumeration of metastatic lung nodules of both mice 
cohorts. The cisplatin-treated mice demonstrated a significantly higher (p  0.01) pulmonary 
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metastatic nodule burden when compared to the vehicle control group (Figure. 1D).  Together, 
these data suggest that cisplatin administration elicits no primary tumor response but does 
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Figure. 4:  Cisplatin treatment elicits no tumor response but exacerbates metastatic burden 
 
A. Primary Tumor growth curves for vehicle versus cisplatin treated cohorts (n = 20/cohort). 
Vehicle and cisplatin  (2.5mg/kg) were administered retro-orbitally weekly, for three weeks. 
Tumor volumes were calculated using the formula : length x (width)2 x 0.52. Tumor volumes 
are shown as mean ± SEM.  
B. Non-invasive bioluminescence imaging to monitor metastatic progression. The luciferase 
signal and luminescence were assessed in vehicle and cisplatin-treated cohorts respectively. 
C. Quantification of metastatic nodules of vehicle and cisplatin treated mice cohorts (n = 5 
/cohort) at experimental endpoint (**, p 0.01). Metastatic nodule number shown as mean ± 
SEM. 



























2. A screen for phage-displayed breast lung metastasis homing peptides 
In order to isolate peptides specifically homing to chemoresistant breast lung 
metastases (BLM), the in vivo phage display methodology was adopted to investigate the 
interactions between phage-peptides mimicking the ligands of novel receptors expressed 
preferentially on the tissues or organs of interest (140, 142, 185). In vivo phage display screening 
was performed in the 4T1 chemoresistant spontaneous TNBC metastasis model described above 
(Figure. 4). This model was chosen because it supports the basis of our hypothesis that upon 
chemoresistance evolution, mammary tumor cells acquire an aggressive phenotype that promotes 
metastatic progression and malignancy-associated morbidity (181, 182).  
In vivo phage display bio-panning was combined with the isolation of metastatic tumor 
cells by fluorescence-activated cell sorting (FACS) from BLM cell suspensions. We focused on 
the isolation of phage-peptides that specifically bound to the mCherry positive cell sub-population 
of BLM from the lung (Figure. 5A). Prior to in vivo phage-peptide bio-panning, insertless Fd-Tet 
phage was intravenously injected into the mouse model for non-specific phage-peptide binding 
normalization. Three rounds of in vivo bio-panning were performed. At the start of the first round, 
a mixture of cyclic CX7C and CX8C (C: disulfide-bonded cysteines; X: any amino acid) random 
phage-peptide libraries were injected into the chemoresistant 4T1 spontaneous metastasis model. 
This approach enabled the selection of pulmonary TNBC metastasis homing phage-peptide 
probes from a pool of over 1010 combinatorial peptides displayed as a fusion on the pIII protein 
of filamentous M13 bacteriophage.  
For every round, the output of the previous round was quantified, amplified, pooled, 
and used as the input of the subsequent rounds. Following each round of bio-panning, the phage-
peptides recovered from the FACS-sorted mCherry positive and mCherry negative cell sub-
populations were individually tittered using K91 E.coli bacterial host cells (Figure. 5B). Only 
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those E.coli cells infected with phage formed plaques on double-layered tetracycline rich LB agar 
plates (Figure. 5B). After titration, the phage binding efficiency was calculated by dividing the 
phage TU by the number of FACS sorted cells. The relative specificity of phage-displayed 
peptides binding to mCherry positive tumor cell populations was compared to that of the mCherry 
negative host cell population. In Rounds 2 and 3, a significant enrichment (p  0.001) in the 
number of phage-peptides homing to mCherry positive metastatic cell populations was observed 
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Figure. 5: An in vivo phage-displayed peptide library screen for peptides homing to cisplatin 
resistant metastatic tumor cells 
A. FACS analysis of mouse lung tissue samples. Tumor cells from pulmonary metastases were 
recovered based on mCherry fluorescence gating. Pulmonary cells recovered from healthy 
tumor-free mice used as gating control. 
B. Comparison of phage infected E.coli plaque density between mCherry positive tumor cells 
from pulmonary metastases and mCherry negative host lung cells over three rounds of in vivo 
phage-displayed peptide library bio-panning. Fd-Tet: Insertless control phage used for 
normalization.  
C. Phage-displayed peptides bound to metastatic mCherry positive tumor cells, in parallel with 
phage-displayed peptides bound to host lung cells, were quantified, amplified, pooled, and 
used for subsequent  rounds of bio-panning. Increased recovery of phage transforming units 
(TU) in successive rounds reflects the enrichment of phage-displayed peptides homing to the 
metastatic mCherry positive tumor cells. Shown are mean ± SEM for duplicate measurements. 
Two-way ANOVA indicates statistically significant differences within mCherry positive and 
mCherr  negative groups assessed b  Sidak s multiple comparisons test and is denoted as: 










3. Nine novel breast lung metastasis homing phage-peptides were identified through  in vivo 
screening of chemoresistant TNBC pulmonary metastases 
After three rounds of synchronous in vivo bio-panning, nine CX7C phage-peptide 
clones were repeatedly recovered from chemoresistant mCherry positive metastatic tumor cells 
with a frequency above 1%. These phage-displayed peptides were termed breast lung metastasis 
peptides (BLMP), BLMP0 through BLMP8 (Figure. 6A). The homing specificity of each clone 
was assessed by quantifying the frequency of phage coding for each peptide. Each BLMP clone 
demonstrated a significant enrichment (p  0.001)  between Rounds 2 and 3 of in vivo phage bio-
panning (Figure. 6A). BLMP7 stood out owing to its marked capacity to home to chemoresistant 
BLM. BLMP7 represented 59.21% of the recovered clones in Round 3. BLMP5, BLMP0, and 
BLMP4 were the next most enriched BLMP clones with a frequency of 8.69%, 6.67%, and 6.58%, 
respectively (Figure. 6A). Although BLMP1, BLMP2, and BLMP3 had relatively high homing 
frequency in Round 2, they were absent in Round 3 (Figure. 6A). Thus, these three BLMP clones 
were excluded from further analysis.  
BLMP0, BLMP4, BLMP5, BLMP6, BLMP7, and BLMP8 were individually amplified 
in K91 E.coli. PCR was performed on the bacteriophage infected E.coli to amplify the fragment 
containing BLMP inserts. The products were analyzed by agarose gel electrophoresis. All BLMP 
clones had a 34 bp-sized insert, unlike insertless Fd-Tet phage (Figure. 6B). Individual BLMP 
clones were then characterized by DNA sequencing. The amino acid sequences of the BLMPs 
were computed from their cognate DNA sequences using the ExPASy bioinformatics portal. The 
amino acid sequences and the overall charge of each BLMP clone were summarized (Figure. 6C). 
The net charge of each clone was calculated as the total of the charge of each amino acid present 
in the BLMP sequence. The insert CLRHSSKIC constituted over 60% of the clones identified by 



























Figure. 6:  Summary of top BLMP clones enriched over three rounds of in vivo phage-
displayed peptide library bio-panning 
A. Assessment of individual BLMP clone frequencies over Round 2 and Round 3 of in vivo phage 
displayed peptide library bio-panning. Shown are mean ± SEM for triplicate measurements. 
Two-way ANOVA indicates statistically significant differences within Rounds 2 and 3 by 
Sidak s multiple comparisons test and is denoted as: ***, p 0.001 and ****, p  0.0001.  
B. Analysis of PCR product size of individual BLMP clones by DNA agarose electrophoresis. 
Fd-Tet : Insertless control cphage. D-WAT: positive control phage.  








BLMP0 CGVLPYSLC Neutral 
BLMP4 CSGVGIASC Neutral 
BLMP5 CEGPMYAKC - 
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4. All BLMP clones bind specifically to murine cancer cell lines in vitro 
The tropism of BLMP clones for TNBC cell lines was further validated through an in 
vitro immunofluorescence assay. This assay was performed using a specific antibody against M13 
filamentous phage. Phage particles displaying the selected BLMP inserts were incubated with 
murine parental and cisplatin-resistant 4T1.2 adenocarcinoma cells and 3T3L1 murine fibroblasts 
overnight. Wild-type insertless Fd-Tet phage was used as negative phage control. The assay 
results demonstrated a pronounced red fluorescence signal for all BLMP clones in both 4T1 
parental and 4T1 cisplatin-resistant TNBC cell lines. Further, no BLMP clone binding (red) was 
observed in murine 3T3L1 fibroblasts. These observations suggest that the BLMP clones, home 
specifically to only TNBC cell lines. However, no significant difference in binding capacity was 
observed between the 4T1 parental and cisplatin-resistant cell lines (Figure. 7A).  
The relative specificity of individual BLMP clones to TNBC cancer cell lines was 
further probed through an internalization assay. Phage particles displaying the selected BLMP 
inserts were incubated overnight with the cell lines described above. Additionally, murine 
melanoma B16F10 cell lines were used to evaluate the possible existence of BLMP clone cross-
reactivity in different murine cancer models.  Upon incubation, the BLMP clones binding to each 
cell line were recovered, pooled, and quantified through titration against K91 E.coli bacteria. 
BLMP binding efficiency was reported as a ratio of phage TU recovered and cell count (Figure. 
7B). Compared to 3T3L1 negative control, all BLMP clones except BLMP5 and BLMP6 showed 
significant binding efficiency  (p  0.0001) to all murine cancer cell lines. Hence, BLMP5 and 
BLMP6 were excluded from further analysis (Figure. 7B). BLMP4 and BLMP7 stood out owing 
to the significant difference (p  0.01) in binding capacity between parental and cisplatin-resistant 
4T1.2 adenocarcinoma cells. BLMP8 stood out owing to its significantly higher (p  0.0001) 














































Figure. 7: Validation of phage-displayed BLMP clone specificity to cancer cells in vitro 
A. Anti-phage (Cy3) immunofluorescence in parental and cisplatin-resistant murine 4T1.2 
adenocarcinoma and 3T3L1 fibroblast cell lines incubated with phage-displayed BLMP 
clones overnight. Red (anti-phage) immunofluorescence signal upon digital channel merging 
indicates localization of BLMP clones on 4T1 parental and cisplatin-resistant cell lines but 
not on 3T3L1 murine fibroblasts. Fd-Tet: Insertless control phage. Nuclear DAPI staining is 
blue. Scale bar: 50 m. 
B. Assessment of individual phage-displayed BLMP clones homing for parental and cisplatin-
resistant murine 4T1.2, murine B16F10 melanoma and murine 3T3L1 fibroblast cell lines. 
Cells were incubated with phage-displayed BLMP clones overnight. Relative specificity of 
phage homing was calculated as a ratio of TU recovered and cell count. Shown are mean ± 
SEM for triplicate measurements. Two-way ANOVA indicates statistically significant 




































differences assessed b  Sidak s multiple comparisons test. *, p  0.01; ***, p  0.001 and 
****, p  0.0001 indicates comparison between  3T3L1 negative control and cancer cell lines 
for the same peptide.  ***, p  0.001 and ****, p  0.0001 indicates comparison between 
parental and cisplatin-treated murine 4T1.2 adenocarcinoma cell lines for the same peptide. 





















5. Both BLMP7 and BLMP8 demonstrate pulmonary metastases-specific tropism in a  
spontaneous TNBC metastasis model 
The tropism of BLMP clones to pulmonary metastases was explored in the 4T1 
adenocarcinoma spontaneous metastasis model. Phage particles bearing the BLMP inserts were 
intravenously injected into vehicle and cisplatin-treated mice (n = 5/cohort). Following the 
systemic circulation of phage for 3 hours, the mice were euthanized. Their organs (lung, primary 
tumor, kidney, pancreas, liver, and brain) were resected and subsequently formalin-fixed for 
future analysis. Immunofluorescence assay was performed in formalin-fixed paraffin-embedded 
organ sections of mice from both vehicle and cisplatin-treated cohorts. The assay was performed 
using a specific antibody against M13 filamentous phage. 
In the vehicle-treated 4T1 mouse model, BLMP7 with CLRHSSKIC motif 
demonstrated localization (red) to the indicated areas of pulmonary metastases and liver. In 
contrast, the primary tumor and other control organs (pancreas, kidney, and brain) showed no 
BLMP7 (red) localization (Figure. 8A). Similar results were observed in the cisplatin-treated 4T1 
mouse model, with additional non-specific BLMP7 (red) trapping in the kidneys and livers of 
cisplatin-treated mice (Figure. 8B). These results suggest that BLMP7 homes specifically to only 
TNBC pulmonary metastases regardless of chemotherapy administration.  
Interestingly, in addition to pulmonary metastases homing, BLMP8 with 
CRAGVGRGC motif, demonstrated localization (red) in the primary tumor as well. However, 
BLMP8 did not localize to other control organs (pancreas and brain). These observations were 
noticed in both vehicle (Figure. 8C) and cisplatin-treated (Figure. 8D) 4T1 mouse models. In the 
cisplatin-treated cohort, additional non-specific BLMP8 (red) trapping in the kidneys and liver 
were noted (Figure. 8D). These results suggest that BLMP8 homes not only to the spontaneous 
pulmonary metastases but also to the original localized TNBC primary tumors. As observed for 
BLMP7, BLMP8 homing was independent of chemotherapy administration.   
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Upon closer analysis of BLMP7 and BLMP8 homing in the indicated areas of 
pulmonary metastases, it was noted that the phage-displayed peptides (red) consistently localized 
along the invasive edges of the macro-metastases (Figures. 8 A-D). Distribution of the phage to 
tumor cells with metastases was further probed through immunofluorescence assay with an 
antibody against Cytokeratin 14 (Basal TNBC marker). In the 4T1 spontaneous metastasis model, 
no co-localization of phage with Cytokeratin 14 was observed (data not shown).  
The pulmonary metastases-specific tropism demonstrated by both BLMP7 and BLMP8 
clones was further corroborated in healthy metastasis-free mice. C57BL/6 mice (n=4) were 
intravenously injected with either BLMP 7 or BLMP8. The organs of the mice were processed as 
described above. Neither BLMP7 nor BLMP8 homed to lung tissue or control organs (pancreas, 
kidney, and brain) of healthy mice (Figures. 9A and 9B).   
BLMP0 and BLMP4 clones were also administered intravenously into vehicle and 
cisplatin-treated mice. Contrary to in vitro BLMP clone homing data discussed above (Figure. 7), 
neither BLMP0 nor BLMP4 homed to TNBC pulmonary metastases or primary tumors (data not 

































Figure. 8: BLMP7 and BLMP8 home to pulmonary metastases in the 4T1 TNBC mouse 
model 
A. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of  
vehicle-treated mice intravenously injected with BLMP7. Red (anti-phage) signal upon digital 
channel merging indicates localization of BLMP7 in the indicated areas of pulmonary 
metastases (b), and liver (e), but not in primary tumor (d), kidney (f), pancreas (g), and        
brain (h). Nuclear DAPI staining is blue. Scale bar: 100 m. 
B. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of  
cisplatin-treated mice intravenously injected with BLMP7. Red (anti-phage) signal upon 
digital channel merging indicates localization of BLMP7 in the indicated areas of pulmonary 
metastases (b), liver (e), and kidney (f), but not in primary tumor (d), pancreas (g), and         
brain (h). Nuclear DAPI staining is blue. Scale bar: 100 m. 
C. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of  
vehicle-treated mice intravenously injected with BLMP8. Red (anti-phage) signal upon digital 
channel merging indicates localization of BLMP8 in the indicated areas of pulmonary 
metastases (b), primary tumor (d), and liver (e), but not in kidney (f), pancreas (g), and        
brain (h). Nuclear DAPI staining is blue. Scale bar: 100 m. 
D. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of  
cisplatin-treated mice intravenously injected with BLMP8. Red (anti-phage) upon digital 
channel merging indicates localization of BLMP8 in the indicated areas of pulmonary 
metastases (b), liver (e), and kidney (f), and primary tumor (d), but not in pancreas (g), and 




















Figure. 9: Absence of BLMP7 and BLMP8 homing in metastases-free mice. Anti-phage (Cy3) 
immunofluorescence in serial paraffin sections of formalin-fixed organs of  tumor-free mice 
intravenously injected with phage-displayed BLMP7 (Figure. 9A) or BLMP8 clones (Figure. 9B). 
Red (anti-phage) immunofluorescence signal upon digital channel merging indicates localization 
of phage observed for both BLMP7 (Figure. 9A) and BLMP8 (Figure. 9B) in liver (c), but not in 





















6. Only BLMP8 demonstrates pulmonary metastases-specific tropism in an experimental 
melanoma metastasis model 
Since neither BLMP7 nor BLMP8 demonstrated chemoresistance specific pulmonary 
metastasis homing, we hypothesized that both BLMP7 and BLMP8 clones might home to 
pulmonary metastases in other cancer sub-type settings. To test this hypothesis, the B16F10 
melanoma mouse model was selected for further analysis. This mouse model was chosen as 
BLMP8 demonstrated a significantly high binding efficiency to murine B16F10 melanoma cells 
in vitro (Figure. 7B). Further, the B16F10 melanoma model is a well-characterized model of 
experimental metastasis (186, 187). Phage particles bearing the BLMP inserts were intravenously 
injected into vehicle and cisplatin-treated B16F10 mouse models (n=3/cohort). Phage circulation, 
organ recovery, and immunofluorescence analysis of formalin-fixed paraffin-embedded organ 
sections was performed as described previously.   
In both vehicle and cisplatin-treated B16F10 mouse model, BLMP7 demonstrated no 
localization (red)  to either pulmonary metastases or control organs (Figures. 10A and 10B). These 
results suggest that BLMP7 homes to pulmonary metastases only in TNBC mouse models. 
Interestingly, BLMP8 (red) demonstrated localization in pulmonary metastases but not to the 
control organs of both vehicle and cisplatin-treated B16F10 mouse models (Figures. 10C and 
10D). Like the 4T1 cisplatin-treated cohort, non-specific BLMP8 (red) trapping in the liver and 
kidneys of B16F10 cisplatin-treated mice was also noted (Figure. 10D). These results suggest that 
BLMP8 homes to pulmonary metastases irrespective of the cancer sub-type setting, thus 
corroborating the translation potential of BLMP8. Further, BLMP8 homing was independent of 
chemotherapy administration.  Similar to the 4T1 spontaneous metastasis model, BLMP8 (red) 
localization within B16F10 pulmonary metastases was observed along the invasive edges of the 
































Figure 10: BLMP8  homes to pulmonary metastases in the B16F10 melanoma mouse model  
A. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of  
vehicle-treated mice intravenously injected with BLMP7. Red (anti-phage) 
immunofluorescence signal upon digital channel merging indicates localization of BLMP7 in 
liver (c), but not in the indicated areas of pulmonary metastases (b), kidney (d), pancreas (e), 
and brain (f). Nuclear DAPI staining is blue. Scale bar: 100 m. 
B. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of  
cisplatin-treated mice intravenously injected with BLMP7. Red (anti-phage) 
immunofluorescence signal upon digital channel merging indicates localization of BLMP7 in 
liver (c), and kidney (d), but not in the indicated areas of pulmonary metastases (b), pancreas 
(e), and brain (f). Nuclear DAPI staining is blue. Scale bar: 100 m.  
C. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of  
vehicle-treated mice intravenously injected with BLMP8. Red (anti-phage) 
immunofluorescence  signal upon digital channel merging indicates localization of BLMP8 
in liver (c), but not in the indicated areas of pulmonary metastases (b), kidney (d), pancreas 
(e), and brain (f). Nuclear DAPI staining is blue. Scale bar: 100 m. 
D. Anti-phage (Cy3) immunofluorescence in serial paraffin sections of formalin-fixed organs of  
cisplatin-treated mice intravenously injected with BLMP8. Red (anti-phage) 
immunofluorescence signal upon digital channel merging indicates localization of BLMP8 in 
liver (c), and kidney (d), but not in the indicated areas of pulmonary metastases (b), pancreas 









7.  BLMP7 and BLMP8 home to mesenchymal tumor cells in lung metastases  
Phage-displayed BLMP localization was restricted to the invasive edges of metastases. 
This prompted us to explore the favorable tumor cell features that attracted phage-displayed 
peptide binding. Thus, the co-localization of BLMP7 and BLMP8 with markers of EMT, E-
cadherin, and N-cadherin, was investigated. In the 4T1 spontaneous metastasis mouse model, 
BLMP7 and BLMP8 localization (red) was absent in pulmonary metastases cells positive for 
epithelial E-cadherin (Figure. 11 A-C). Further, a similar trend was observed in the primary 
tumors obtained from mice injected with phage-displayed BLMP8 (Figure. 11B and 11C). In the 
B16F0 experimental metastasis mouse model, BLMP8 (red) also demonstrated a localization 
pattern similar to 4T1 spontaneous pulmonary metastases (Figure. 11D). In this model, only 
BLMP8 co-localization was probed due to a lack of BLMP7 homing to B16F10 pulmonary 
metastases. These observations remained consistent across the vehicle and cisplatin-treated 
models.  
However, in the 4T1 spontaneous metastasis mouse model, both BLMP7 and BLMP8 
co-localized (yellow) with N-cadherin positive pulmonary metastatic tumor cells (Figure. 12 A-
C). Further, a similar trend was observed in the primary tumors obtained from mice injected with 
phage-displayed BLMP8 (Figure. 12B and 12C). In the B16F0 experimental metastasis mouse 
model, BLMP8 also demonstrated a localization pattern similar to 4T1 spontaneous pulmonary 
metastases (Figure. 12D). In this model, only BLMP8 co-localization was probed due to a lack of 
BLMP7 homing to B16F10 pulmonary metastases. These observations remained consistent across 
vehicle and cisplatin-treated models. Taken together, these data suggest that phage-displayed 


































Figure 11: BLMP7 and BLMP8  do not home to E-cadherin positive tumor cells  
A. Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in serial paraffin 
sections of formalin-fixed pulmonary metastases of vehicle and cisplatin-treated 4T1 mouse 
models, intravenously injected with BLMP7. Upon digital channel merging, the absence of 
red (anti-phage) and green (E-cadherin) immunofluorescence co-localization indicates that 
BLMP7 doesn t home to E-cadherin positive tumor cells in both vehicle (b) and cisplatin-
treated (d) pulmonary metastases. Nuclear DAPI staining is blue. Scale bar: 100 m.  
B. Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in serial paraffin 
sections of formalin-fixed pulmonary metastases and primary tumors of vehicle-treated 4T1 
mouse model, intravenously injected with BLMP8. Upon digital channel merging, the absence 
of red (anti-phage) and green (E-cadherin) immunofluorescence co-localization indicates that 
BLMP8 doesn t home to E-cadherin positive tumor cells in vehicle-treated pulmonary 
metastases (b) and primary tumors (d). Nuclear DAPI staining is blue. Scale bar: 100 m. 
C. Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in serial paraffin 
sections of formalin-fixed pulmonary metastases and primary tumors of cisplatin-treated 4T1 
mouse model, intravenously injected with BLMP8. Upon digital channel merging, the absence 
of red (anti-phage) and green (E-cadherin) immunofluorescence co-localization indicates that 
BLMP8 doesn t home to E-cadherin positive tumor cells in cisplatin-treated pulmonary 
metastases (b) and primary tumors (d). Nuclear DAPI staining is blue. Scale bar: 100 m. 
D. Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in serial paraffin 
sections of formalin-fixed pulmonary metastases of vehicle and cisplatin-treated B16F10 
mouse models, intravenously injected with BLMP8. Upon digital channel merging, the 
absence of red (anti-phage) and green (E-cadherin) immunofluorescence co-localization 
indicates that BLMP7 doesn t home to E-cadherin positive tumor cells in both vehicle (b) and 























































Figure 12: BLMP7 and BLMP8 home to N-cadherin positive tumor cells  
A. Anti-phage (Cy3) and anti N-cadherin (Alexa-488) immunofluorescence in serial paraffin 
sections of formalin-fixed pulmonary metastases of cisplatin and vehicle-treated 4T1 mouse 
models, intravenously injected with BLMP7. The co-localization of red (anti-phage) and 
green (N-Cadherin) signals upon digital channel merging indicates that BLMP7 does home to 
N-cadherin positive tumor cells in cisplatin (b) and vehicle-treated (d) pulmonary metastases. 
Nuclear DAPI staining is blue. Scale bar: 100 m. 
B. Anti-phage (Cy3) and anti N-cadherin (Alexas-488) immunofluorescence in serial paraffin 
sections of formalin-fixed pulmonary metastases and primary tumors of vehicle-treated 4T1 
mouse model, intravenously injected with BLMP8. The co-localization of red (anti-phage) 
and green (N-Cadherin) signals upon digital channel merging indicates that BLMP8 does 
home to N-cadherin positive tumor cells in vehicle-treated pulmonary metastases (b) and 
primary tumors (d). Nuclear DAPI staining is blue. Scale bar: 100 m. 
C. Anti-phage (Cy3) and anti N-cadherin (Alexas-488) immunofluorescence in serial paraffin 
sections of formalin-fixed pulmonary metastases and primary tumors of cisplatin-treated 4T1 
mouse model, intravenously injected with BLMP8. The co-localization of red (anti-phage) 
and green (N-Cadherin) signals upon digital channel merging indicates that BLMP8 does 
home to N-cadherin positive tumor cells in cisplatin-treated pulmonary metastases (b) and 
primary tumors (d). Nuclear DAPI staining is blue. Scale bar: 100 m. 
D. Anti-phage (Cy3) and anti N-cadherin (Alexa-488) immunofluorescence in serial paraffin 
sections of formalin-fixed pulmonary metastases of vehicle and cisplatin-treated 4T1 mouse 
models, intravenously injected with BLMP8. The co-localization of red (anti-phage) and 
green (N-Cadherin) signals upon digital channel merging indicates that BLMP8 does home to 
N-cadherin positive tumor cells in vehicle (b) and cisplatin-treated (d) pulmonary metastases. 
Nuclear DAPI staining is blue. Scale bar: 100 m. 
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8. Phage-displayed BLMP7 and BLMP8 do not home to epithelial tumor cells in vitro  
In order to corroborate that BLMP7 and BLMP8 do home to mesenchymal tumor cells, 
we investigated the BLMP homing pattern in vitro with an immunofluorescence assay, using a 
specific antibody against epithelial marker E-cadherin. Phage-displayed BLMP7 and BLMP8 
were incubated with murine parental and cisplatin-resistant 4T1.2 adenocarcinoma cells, murine 
B16F10 melanoma and human MDA-MB-231 adenocarcinoma cells overnight.  
All cell lines, including B16F10 and MDA-MB-231 cells, demonstrated BLMP7 (red) 
and BLMP8 (red) binding (Figures. 13 A-H). Further, it was observed that 4T1 cells with 
pronounced E-cadherin (green) expression demonstrated less BLMP7 and BLMP8 binding (green 
arrow). Instead, both BLMP7 and BLMP8 (white arrow) were seen to bind better to cancer cells 
with very little to no E-cadherin expression (Figures. 13 A-H). Loss in the E-cadherin expression 
is a characteristic feature of cells undergoing EMT, to acquire a more mesenchymal phenotype. 
Since phage-displayed peptide homing in seen in tumor cells exhibiting predominantly 
mesenchymal characteristics,  these data suggest that phage-displayed BLMP7 and BLMP8 home 























Figure 13: BLMP7 and BLMP8 home to tumor cells expressing reduced levels of  E-
cadherin Anti-phage (Cy3) and anti E-cadherin (Alexa-488) immunofluorescence in murine 
parental and cisplatin-resistant 4T1.2 adenocarcinoma, human MDA-MB-231 adenocarcinoma 
and murine B16F10 melanoma cell lines. Cells were incubated with phage-displayed BLMP7 and 
BLMP8 clones overnight. Upon digital channel merging, cancer cells exhibiting high level of 
green (E-cadherin) signal (green arrow), demonstrate lesser homing of BLMP7 (Cy3) and BLMP8 
(Cy3) clones. However, cancer cells exhibiting little to no green signal (white arrow), demonstrate 
more specific homing of phage-displayed BLMP7 (Cy3) and BLMP8 (Cy3) clones. Nuclear 
































9. Biotin-labeled HK-BLMP7 and HK-BLMP8 bind specifically to cancer cell lines in vitro 
In order to explore the binding specificity of BLMP7 and BLMP8 outside the phage 
context, hunter-killer peptide versions of BLMP7 and BLMP8, termed HK-BLMP7 and HK-
BLMP8, were chemically synthesized. HK-BLMP7 consists of homing motif CLRHSSKIC 
conjugated with the KLAKLAKKLAKLAK sequence, with an amino-hexanoic acid linker. HK-
BLMP8 was designed in a similar manner, with a homing motif of CRAGVGRGC instead. The 
amphipathic peptide (KLAKLAK)2 sequence, disrupts cellular mitochondrial membranes through 
receptor-mediated cell internalization, to promote programmed cell death (188).  
The tropism of HK-BLMP7 and HK-BLMP8 for cancer cell lines was probed through 
biotin labeling. The pro-apoptotic potential of HK-BLMP7 and HK-BLMP8 was neutralized 
through the binding of biotin molecules to (KLAKLAK)2 s l sine residues. Biotin-labeled HK-
BLMP7 (B-BLMP7) and biotin-labeled HK-BLMP8 (B-BLMP8) were incubated with murine 
parental and cisplatin-resistant 4T1.2 adenocarcinoma cells, murine B16F10 melanoma, human 
MDA-MB-231 adenocarcinoma, and 3T3L1 murine fibroblasts for six hours. This was followed 
by an in vitro immunofluorescence assay using a Cy3-conjugated streptavidin binding to biotin 
on the labeled peptides. Human MDA-MB-231 adenocarcinoma cells were used to study the 
translational potential of the hunter-killer peptides. 3T3L1 fibroblasts were used as a negative 
control. The results of the assay demonstrated a pronounced red (Cy3) fluorescence signal for 
both B-BLMP7 (Figures. 14 A-D) and B-BLMP8 (Figures. 14 F-I) in all cancer cell lines. 
However, no signal that could result from peptide binding was observed in murine 3T3L1 
fibroblasts (Figures. 14E and 14J). These observations indicate that B-BLMP7 and B-BLMP8 






Figure 14: Validation of biotin-labeled HK-BLMP7 (B-BLMP7) and biotin-labeled HK-
BLMP8 (B-BLMP8) homing specificity to cancer cells in vitro (A-J). Streptavidin (Cy3) 
immunofluorescence in murine parental and cisplatin-resistant 4T1.2 adenocarcinoma, murine 
B16F10 melanoma, human MDA-MB-231 adenocarcinoma, and murine 3T3L1 fibroblast cell 
lines. Cells were incubated with B-BLMP7 and B-BLMP8 for 6 hours. Red (Streptavidin) 
immunofluorescence signal upon digital channel merging indicates localization of B-BLMP7 
(Cy3) and B-BLMP8 (Cy3) on 4T1 parental, 4T1 cisplatin resistant, B16F10 and MDA-MB-231 



















10. Biotin-labeled HK-BLMP8 does not home to epithelial tumor cells in vitro  
As discussed earlier, phage-displayed BLMP8 did not bind to epithelial cancer cells in 
vitro (Figures. 13 E-H). In order to corroborate that the chemically synthesized B-BLMP8 also 
demonstrated the same binding pattern, we investigated B-BLMP8 (red) homing in vitro with an 
immunofluorescence assay, using a specific antibody against epithelial marker E-cadherin 
(green). B-BLMP8 was incubated with murine parental and cisplatin-resistant 4T1.2 
adenocarcinoma cells, murine B16F10 melanoma, and human MDA-MB-231 adenocarcinoma 
cells for six hours.  
As seen with phage-displayed BLMP8, B-BLMP8 (red) was observed to bind less to 
cancer cells with pronounced E-cadherin (green) expression (green arrow). Instead, B-BLMP8 
(white arrow) was seen to bind better to cancer cells with very little to no E-cadherin expression 
(Figures. 15 A-D). Loss in the E-cadherin expression is a characteristic feature of cells undergoing 
EMT, to acquire a more mesenchymal phenotype. Taken together, these data suggest that like 
phage-displayed BLMP8, its synthetically synthesized version B-BLMP8 also binds to cells with 














Figure 15: B-BLMP8 homes to tumor cells expressing reduced levels of  E-cadherin 
(A-D). Streptavidin (Cy3) and anti E-cadherin (Alexas-488) immunofluorescence in murine 
4T1.2 parental and cisplatin-resistant adenocarcinoma, murine B16F10 melanoma and human 
MDA-MB-231 adenocarcinoma cancer cell lines. Cells were incubated with B-BLMP8 for six 
hours. Upon digital channel merging, cancer cells exhibiting high level of green (E-cadherin) 
immunofluorescence signal (green arrow), demonstrate lesser homing of B-BLMP8 (Cy3). 
However, cancer cells exhibiting little to no green immunofluorescence signal (white arrow), 




11. HK-BLMP8 induces cell death in murine cancer cell lines in vitro 
The ability of hunter-killer peptides to induce programmed-cell death in vivo and in 
vitro is a well-documented phenomenon (145, 189-191). A cell viability assay using different 
hunter-killer peptides was performed in murine parental and cisplatin-resistant 4T1.2 
adenocarcinoma cells, B16F10 melanoma, and 3T3L1 fibroblasts cell lines. The cells were treated 
with HK-BLMP7 (300 moles/L), varying concentrations of HK-BLMP8 (100-200 moles/L), 
positive-control D-CAN (100 moles/L), and uncoupled (KLAKLAK)2 moiety (100 moles/L) 
for 8 hours. Cell death was then evaluated through trypan blue staining.  
At the eight-hour time point, D-CAN induced non-specific apoptosis in both murine 
cancer cells and 3T3L1 fibroblasts (Figures. 16A and 16B). As previously described, no apoptosis 
induction was seen upon treatment with the uncoupled (KLAKLAK)2 moiety owing to the 
absence of a homing domain (Figures. 16A and 16B). Treatment with HK-BLMP7 induced no 
cell death in any of the cells at the eight-hour time point. Upon treatment extension to twenty-four 
hours, a small degree of cell death was observed in both murine cancer cell lines and 3T3L1 cells 
(Figures. 16A and 16B). On the other hand, at the eight-hour time point, HK-BLMP8 induced 
apoptosis at both 100 moles/L and 200 moles/L concentrations, specifically in murine cancer 
cell lines (data not shown). To investigate if HK-BLMP8 induced apoptosis was cancer cell-
specific, the treatment period was increased to twenty-four hours. At this new time point, HK-
BLMP8 induced complete cell death in nearly all cancer cell lines but not in 3T3L1 fibroblasts 
(Figures. 16A and 16B).  Although both HK-BLMP7 and  HK-BLMP8 induce cancer cell 
apoptosis in vitro, HK-BLMP8 was a more suitable candidate owing to its specificity to only 
cancer cell lines and not 3T3L1 fibroblasts. Further, in vitro immunostaining corroborated that 






























Figure 16: HK-BLMP7 and HK-BLMP8 induce apoptosis in cell culture 
A. Cell viability assay of murine 4T1 parental, 4T1 cisplatin resistant, B16F10 and 3T3L1 
fibroblast cell lines following treatment with uncoupled (KLAKLAK)2 (100 moles/L), D-
CAN (100 moles/L),  HK-BLMP7 (300 moles/L) or HK-BLMP8 (100 to 200 moles/L). 
Cell death was evaluated by Trypan blue staining. Uncoupled (KLAKLAK)2: negative control 
and D-CAN: positive control.  
B. Brightfield images of dead cells (Trypan blue positive) after treatment with uncoupled 
(KLAKLAK)2 (100 moles/L), D-CAN (100 moles/L), HK-BLMP7 (300 moles/L) or HK-
BLMP8 (100 moles/L). Uncoupled (KLAKLAK)2: negative control and D-CAN: positive 


















Figure 17: HK-BLMP8 induces cleaved caspase-3 mediated apoptosis in murine cancer cell 
lines in vitro. Cleaved Caspase-3 (red) immunofluorescence in murine 4T1 parental, 4T1 cisplatin 
resistant, and negative control 3T3L1 murine fibroblast cell lines treated with HK-BLMP8 (100 
moles/L) for 8 hours. Red (cleaved caspase-3) signal upon digital channel merging indicates 













12. HK-BLMP8 administration induces a modest reduction in 4T1 pulmonary metastatic 
burden but does not improve overall survival  
Based on the in vitro cell viability and cleaved caspase-3 staining results, we 
investigated whether HK-BLMP8 peptide could be used for the therapeutic destruction of 
pulmonary metastases. We injected spontaneously metastasizing dual-luciferase and mCherry 
labeled  4T1 adenocarcinoma cells into Balb/c mice. Once the tumors became palpable, the mice 
were randomized into two cohorts (n=5/cohort) and treated with vehicle control or 10 mg/kg HK-
BLMP8 subcutaneously for four weeks. Tumors were measured thrice a week. Further, the effect 
of vehicle or HK-BLMP8 administration on metastatic progression was monitored weekly 
through non-invasive bioluminescence imaging. Following the administration of the last dose, the 
mice were monitored for survival analysis.  
Based on Welch s t-test analysis, no significant difference (p=0.5735) in tumor 
volumes was observed between the two groups during and after treatment (Figure. 18A). These 
results suggest that the HK-BLMP8 administration did not affect primary tumor growth. Further, 
the Log-Rank (Mantel-Cox) test demonstrated no significant difference (p = 0.9626) in OS 
between the two groups (Figure. 18B). However, upon analysis of non-invasive bioluminescence 
images of the mice, a significant difference in metastatic burden was indicated between the groups 
(Figure. 18C). In the HK-BLMP8 treated mouse cohort, cancer progression and subsequent 
pulmonary metastatic burden were significantly lower when compared to the vehicle-treated 
mouse cohort (Figure. 18C). These observations were further corroborated through pulmonary 
metastases nodule quantification. At the experimental endpoint, the mouse lungs were subjected 
to PBS perfusion. The lungs were then fixed in formalin until the metastatic nodules were 
bleached to amelanotic gray/white nodules (Figure. 18D). This was followed by a blind 
enumeration of metastatic lung nodules of both mice cohorts. The HK-BLMP8 treated mice 
demonstrated a significantly lower (p  0.01) pulmonary metastatic nodule burden when 
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compared to the vehicle control group (Figure. 18E).  Together, these data suggest that HK-
BLMP8 administration induces a modest reduction in metastatic burden, even though it does not 
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Figure 18: HK-BLMP8 administration reduces metastatic burden but does not 
improve overall survival in vivo 
A. Primary tumor growth curves for vehicle versus HK-BLMP8 treated cohorts (n = 5 
mice/cohort). Vehicle and HK-BLMP8 (10mg/kg) were administered subcutaneously thrice 
week, for twelve weeks. Tumor volumes were calculated using the formula : length x (width)2 
x 0.52. Tumor volumes are shown as mean ± SEM.  
B. Survival of mice post vehicle or HK-BLMP8 (10mg/kg) administration was monitored. The 
probability of survival was depicted using Kaplan-Meier curves. ns, p >0.05.  
C. Non-invasive bioluminescence imaging to monitor the effect of vehicle and HK-BLMP8 
(10mg/kg) on cancer progression and metastatic burden over five weeks. The luciferase signal 
and luminescence were assessed in vehicle and HK-BLMP8 treated cohorts respectively. 
D. Representative images of primary tumors and lung metastases in vehicle and HK-BLMP8 
treated mice cohorts.  
E. Quantification of metastatic nodules of vehicle and HK-BLMP8 treated mice cohorts (n = 5 



































Throughout disease progression, tumor cells undergo spatial and functional changes 
that manifest in a complex sub-clonal architecture, further enhanced by the application of 
chemotherapeutic drugs (192). The existence of spatial intra-tumoral heterogeneity accounts for 
the initiation of tumor clonal evolution and subsequent chemoresistance. Tumor cell diversity 
occurs due to progressive mutational changes that result in distinct cancer cell populations (193). 
Relapse and metastatic progression after a positive therapeutic effect often occur due to a resistant 
population that was present before therapy or originated as a result of chemotherapy. Survival, 
proliferation, and subsequent dominance of this population could be due to features that were 
absent before therapy. Thus, it is crucial to gain more insight into players implicated in the 
survival of these chemotherapy-tolerant metastasis-inducing tumor cell populations.  
TNBCs demonstrate a lack of response to targeted therapies. Therefore, chemotherapy 
remains a mainstay in TNBC treatment. Although TNBCs demonstrate chemosensitivity, the 
evolution of chemoresistance occurs over time. Drug resistance promotes TNBC relapse and is a 
predilection for the development of distant metastases in organs such as the lung, brain, and liver 
(194). TNBC s well-documented resistance to chemotherapy and aggressive phenotype provides 
the ideal setting to study metastatic progression.  We selected the 4T1 murine mammary 
adenocarcinoma model for our study as it accurately portrays stage IV human TNBC (195). 
Moreover, it has been used to study chemotherapy-mediated metastatic progression (196, 197).  
Upon primary tumor development in the 4T1 model, the DNA cross-linking agent 
cisplatin was administered to inhibit cancer progression. The selection of this chemotherapeutic 
agent was primarily due to the renewed interest in using platinum salts in the clinical management 
of human TNBC (198, 199). Although the cisplatin administration failed to elicit any primary 
tumor response,  we report that it exacerbated pulmonary metastasis in the 4T1 murine model of 
spontaneous metastasis. These observations suggest the possibility of a chemotherapy-induced 
enrichment of tumor cell populations favoring metastatic progression. While the adverse side 
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effects of chemotherapeutics have been observed for decades, the role played by chemotherapy 
in actively triggering metastatic progression has only recently been brought to light (178, 200, 
201).  
Targeting these drug-tolerant metastases initiating tumor cells was our next logic step 
forward. As described previously, phage display technology has been used in the isolation and 
targeting of several molecular targets involved in carcinogenesis. While drugs targeting tumor 
cells and other stromal components of the TME have been identified using this methodology, the 
recognition of molecules for selective targeting of drug-tolerant TNBC metastatic tumor cells is 
yet to be performed. We report the isolation of nine novel peptides by phage display (using a 
combined 7-mer and 8-mer phage-displayed peptide libraries), which revealed high selectivity 
and binding efficiency towards tumor cells in the pulmonary metastases of the 4T1 murine 
adenocarcinoma model. Between each round of bio-panning, the BLMP clones were sequenced, 
and nine different homing peptides were identified. In vivo enrichment and in vitro preference 
towards the cisplatin-resistant 4T1.2 cells, demonstrated by BLMP7 (motif: CLRHSSKIC), 
prompted its selection for further analysis. BLMP8 (motif: CRAGVGRGC) was also a candidate, 
owing to its homing to both 4T1 and B16F10 melanoma cells that form lung metastases.  
To further validate the binding affinity and to substantiate our proposed hypothesis, 
phage-displayed BLMP7 and BLMP8 were intravenously injected into mice. The 
immunofluorescence assay on formalin-fixed paraffin-embedded tissue sections of these mice 
revealed a pulmonary metastases-specific tropism exhibited by both BLMP7 and BLMP8. The 
homing of BLMP7 and BLMP8 was also observed in the liver. This can be explained by non-
specific entrapment of phage within the reticuloendothelial system of the liver (202, 203). Phage 
homing specificity was further corroborated by the absence of BLMP7 and BLMP8  localization 
in control organs such as the brain, kidney, and pancreas. Interestingly, in addition to the 
pulmonary metastases, phage-displayed BLMP8 also exhibited tropism to primary 4T1 tumors.  
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In the cisplatin-treated mice cohort, BLMP7 and BLMP8 localization patterns were 
similar to that of the vehicle-treated cohort. Thus, this suggests that BLMP7 and BLMP8 homing 
to metastases occur irrespective of chemotherapy in vivo. Interestingly, localization of BLMP7 
and BLMP8 phage in the kidneys of cisplatin-treated mice was observed. We believe that 
cisplatin-induced nephrotoxicity is partly responsible for the accumulation of phage in the 
kidneys. To gain more insight into this unusual phenomenon, we analyzed the homing patterns of 
BLMP7 and BLMP8 in healthy disease-free C57BL/6 mice. With the exception of liver 
entrapment, neither BLMP7 nor BLMP8 demonstrated localization to kidneys or other control 
organs.  
To explore the possibility of BLMP homing to the metastases of other cancer types, the 
localization of both BLMP7 and BLMP8 was further probed in the murine B16F10 melanoma 
model of experimental metastasis. This model was selected due to lung colonization of the 
implanted B16F10 melanoma cells (186, 187). Phage displaying BLMP8 demonstrated a high 
binding efficiency to murine B16F10 cells in vitro. Like in the 4T1 murine model, BLMP8 
demonstrated a chemotherapy-independent homing to the pulmonary metastases of the B16F10 
murine model. However, BLMP7 showed no localization. Thus, this led us to conclude that 
BLMP8 exhibits cross-tumor type reactivity and homes to pulmonary metastases regardless of 
cancer subtype. In contrast, BLMP7 demonstrates binding only to TNBC cells. Despite BLMP7 
and BLMP8 homing being independent of chemotherapy administration, their metastasis-specific 
tropism bolsters the novelty of our findings. Further, it underscores the potential of using these 
peptides in the development of metastases-specific therapeutics with potentially reduced off-
target effects.  
Analysis of BLMP7 and BLMP8 distribution revealed localization along the invasive 
edge of pulmonary metastases. This pattern was also demonstrated by BLMP8 in primary tumors. 
In many cancers, including TNBC, metastasis is facilitated by the transitioning of tumor cells 
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from a non-motile, epithelial phenotype into a migratory, mesenchymal-like phenotype via EMT 
(28, 29). An EMT hallmark is the loss of epithelial cadherin (E-cadherin) expression and the 
concomitant up-regulation of neural cadherin (N-cadherin) (204). This so-called cadherin 
switch  is associated with increased migratory behavior and inferior disease prognosis (33). A 
major consequence of N-cadherin up-regulation is the loss of stable epithelial cell-cell adhesive 
junctions, apicobasal cell polarity, and epithelial tissue structure, thereby facilitating the 
dissemination of cancer cells from the primary tumor site. Thus, N-cadherin acquisition is a 
critical step in metastatic progression (205). 
An immunofluorescence assay was performed on formalin-fixed paraffin-embedded 
tissue sections of mice injected with phage-displayed BLMP7 and BLMP8 inserts. When phage 
co-localization with epithelial and mesenchymal cadherins was investigated, it was observed that 
both phage-displayed peptides homed to tumor cells with up-regulated N-cadherin expression. No 
phage was seen to bind E-cadherin-positive tumor cells in pulmonary metastases. An identical co-
localization pattern was observed for phage-displayed BLMP8 in the primary tumors of the 4T1 
spontaneous metastasis model, as well as for the pulmonary metastases in the B16F10 
experimental metastasis model. These findings were further corroborated in cell culture, where it 
was observed that phage-displayed BLMP7 and BLMP8 bound better to 4T1.2 murine 
adenocarcinoma cells with reduced E-cadherin expression. Further, it was noticed both BLMP 
clones bound to the cell line (TNBC) MDA-MB-231 model, described as a representative of the 
mesenchymal phenotype of cancer cells (206). These results suggest that BLMP7 and BLMP8 
have an affinity for tumor cells exhibiting mesenchymal-like characteristics. Although there are 
several markers that have to be considered while defining the mesenchymal status of a cancer cell, 
we segregated cells based on the level of E-cadherin expression (207). Reduced E-cadherin 
expression is frequently correlated with increased invasion, making it an ideal marker for the 
identification of metastatic tumor cells (208). 
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Although localized primary tumors are the source of malignancy burden, it is the 
metastases that attribute to over 90% of all cancer-associated morbidity and mortality (19). This 
is the case even in TNBC (20, 209). Our in vivo phage-peptide library bio-panning has yielded 
two metastasis specific peptides demonstrating a unique affinity towards tumor cells with 
mesenchymal-like features. These findings prompted us to explore the therapeutic potential of 
these peptides by translating them into agents targeting mesenchymal-like tumor cells, thus 
curtailing tumor growth and progression. Previous studies have established a strategy of tumor 
cell ablation via hunter-killer  peptides (142, 169, 189). Based on this strategy, we successfully 
coupled our pulmonary metastases homing peptides with an apoptosis-inducing (KLAKLAK)2 
moiety (188).  
Hunter-killer peptide versions of both BLMP7 and BLMP8 termed HK-BLMP7 and 
HK-BLMP7 were synthesized as all D-amino acid peptides to minimize proteolytic cleavage. We 
first validated biotin-labeled HK-BLMP7 and HK-BLMP8 internalization into mesenchymal-like 
tumor cells. As expected, both HK-BLMP7 and HK-BLMP8 bound to tumor cells with reduced 
E-cadherin expression outside the phage context. We next used these novel hunter-killer peptides 
to reduce tumor cell viability in cell culture. Both HK-BLMP7 and HK-BLMP8 induced 
concentration-dependent apoptosis. However, only HK-BLMP8 induced apoptosis specifically of 
tumor cells. Investigation of HK-BLMP8 s mechanism of action revealed that it induced 
programmed cell death via cleaved caspase-3 activation.  
Given our results in cell culture, we proceeded to test  HK-BLMP8 in vivo, using the 
4T1 murine model of spontaneous metastasis. The goal of this study was to; a) determine the 
working dose at which HK-BLMP8 might limit pulmonary metastatic nodule formation and, b) 
explore if the reduction in pulmonary metastatic burden might affect overall survival. Using HK-
BLMP8, we observed a two-fold reduction in pulmonary metastastatic burden. However, the 
statistical significance of this result is yet to be determined in repeated experiments with larger 
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animal numbers. Peptide administration did not elicit any primary tumor response, nor did it 
improve overall survival. The absence of primary tumor response corroborates HK-BLMP8 s 
higher affinity for pulmonary metastases. It should be noted that we administered HK-BLMP8  at 
a low dose (10mg/kg), to minimize off-target adverse effects on mouse health. The lack of survival 
improvement could also be due to mice succumbing to metastatic burden at distant sites other 
than the lungs.  
The physiochemical properties of peptides due to electric charge may partly explain the 
proclivity of the BLMP clones towards tumor cells. Both BLMP7 and BLMP8 have a net positive 
charge. Therefore, their attraction and binding could be in part due to the negative charge of the 
tumor cell surface (210, 211). However, peptide homing is also mediated by differentially-
expressed receptors (179, 212, 213). Thus, we hypothesize that the BLMP clones might bear a 
resemblance to the cancer-related ligands, owing to their specificity for tumor cells. To explore 
this hypothesis,  multiple sequence alignment and BLAST analysis were conducted. Through this 
analysis, we were able to, a) identify promising cancer-specific ligands the BLMP clones were 
homologous with, b) narrow down the cognate cancer putative receptors, and c) investigate if 
these receptors mediated EMT activation since the BLMP clones homed to tumor cells with 
mesenchymal features.  
Multiple sequence alignment and BLAST analysis of BLMP7 and BLMP8 revealed their 
resemblance to cancer-related proteins responsible for mediating chemoresistance and metastatic 
progression. For BLMP7, BLAST analysis identified Mucin5B (MUC5B) to match BLMP7 with 
a 66% amino acid similarity. The mucin family of proteins is often implicated in the progression 
of human carcinomas and hematological malignancies (214). MUC5B is a secreted mucin 
containing tandem repeat structures composed of prolines, threonines, and serines (214). Aberrant 
MUC5B expression is mediated by injured alveolar epithelial cells in both idiopathic pulmonary 
fibrosis (IPF) and lung adenocarcinomas (215, 216). Further, several IPF events such as fibroblast 
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recruitment and proliferation, the formation of myofibroblastic foci due to EMT, ECM 
accumulation, and lung remodeling are even observed in cancers (217). MUC5B regulates the IPF 
phenotype by binding to the promoter region of NF- B and subsequently activating downstream 
signaling (216). The significance of NF- B as a prognostic marker and its role in EMT and 
metastasis has been well-elucidated in breast cancer (218, 219).  
Blast Analysis of BLMP8, revealed a 100% amino acid identity  with murine latent 
transforming growth factor-beta binding protein 4 (LTBP4). LTBP4 serves as a TGF  chaperone 
and also maintains TGF R stability (220). Further, some studies also suggest that LTBP4 is a 
crucial regulator of the TGF /TGF R signaling axis (221). Moreover, altered LTP4 expression 
has been observed in the malignant tissue of both murine and human mammary carcinomas (222). 
Overexpression of TGF  triggers dysregulated TGF /TGF R downstream signaling, which is 
often associated with chemoresistance, EMT induction, and metastatic progression (223, 224). 
TGF  signaling pathwa  is a recogni ed mediator of breast cancer-associated chemoresistance, 

















Chapter 6: Conclusions 











In this study, we have successfully identified two novel peptides, BLMP7 and BLMP8 
through in vivo phage-displayed peptide library screening against pulmonary metastases of the 
4T1 murine model of spontaneous metastasis in the context of chemotherapy. To this end, no 
other study has reported metastases-specific peptides. Our data show a high enrichment of the 
selected peptides over several bio-panning rounds and selective binding to murine and human 
tumor cell lines exhibiting mesenchymal-like features in vivo and in vitro. The evolution of novel 
therapeutics targeting tumor cells with enhanced invasive and migratory potential is a promising 
step in the clinical management and treatment of metastatic disease. Future analysis underlying 
binding experiments for these peptides could be useful in the isolation of their cognate receptors. 
Identification of these metastatic cell surface receptors will help gain more insight into their 
downstream signaling mechanism counterparts and mechanisms. 
Theranostic compounds are a promising class of radioactive contrasting agents. Over 
the past decade, these agents have been instrumental in improving disease outcomes owing to 
their ability to accurately facilitate whole-body and intraoperative imaging (225). The metastases-
specific tropism by the BLMP clones prompted us to explore the potential of developing these 
peptides into malignancy-probing theranostic agents. In collaboration with Dr. Ali Azhdarinia 
(MDACC, Houston), we are conjugating the BLMP clones to radiolabeled domains using 
bifunctional DOTA and NODAGA chelators (226). We hope to delve deeper and gain more 
insight into the mechanisms underlying cancer progression through near-infrared fluorescence 
imaging with these compounds. 
Targeted hunter-killer peptides represent a promising class of novel anti-cancer agents.  
Their therapeutic benefit can be optimized by adjusting properties such as domain length, residue 
placement, peptide hydrophobicity, and hydrophobic moment (227). Beyond this, future hunter-
killer peptides might be designed to promote cell ablation using different cytotoxic domains. Our 
results provide a glimpse at a potential anti-metastasis therapy combining two levels of 
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specificit : homing  to targeted cells and selective apoptosis of such cells upon internalization. 
HK-BLMP8 is a novel pulmonary metastases-ablating peptide that demonstrates modest benefit 
when employed in vivo. Through the conduction of detailed efficacy studies and the adjustment 
of peptide properties mentioned above, we hope to potentiate this hunter-killer peptide candidate's 
overall activity. We believe that using this hunter-killer peptide synergistically with classical 
chemotherapy agents will not only push the boundaries of existing translational medicine but will 
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